NATIONAL INSTRUMENTS CORP (Form: 10-Q, Received: 11/01/2021 13:37:28)

000093549412/312021Q3FALSE31P1YP3YP5YP10YP3YP5YP3YP5YP3YP4YP5YP5YP1YP2YP3Y20000009354942021-01-012021-09-30xbrli:shares00009354942021-10-28iso4217:USD00009354942021-09-3000009354942020-12-31iso4217:USDxbrli:shares0000935494us-gaap:ProductMember2021-07-012021-09-300000935494us-gaap:ProductMember2020-07-012020-09-300000935494us-gaap:ProductMember2021-01-012021-09-300000935494us-gaap:ProductMember2020-01-012020-09-300000935494us-gaap:MaintenanceMember2021-07-012021-09-300000935494us-gaap:MaintenanceMember2020-07-012020-09-300000935494us-gaap:MaintenanceMember2021-01-012021-09-300000935494us-gaap:MaintenanceMember2020-01-012020-09-3000009354942021-07-012021-09-3000009354942020-07-012020-09-3000009354942020-01-012020-09-3000009354942019-12-3100009354942020-09-300000935494us-gaap:CommonStockMember2021-06-300000935494us-gaap:AdditionalPaidInCapitalMember2021-06-300000935494us-gaap:RetainedEarningsMember2021-06-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000009354942021-06-300000935494us-gaap:RetainedEarningsMember2021-07-012021-09-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000935494us-gaap:CommonStockMember2021-07-012021-09-300000935494us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000935494us-gaap:CommonStockMember2021-09-300000935494us-gaap:AdditionalPaidInCapitalMember2021-09-300000935494us-gaap:RetainedEarningsMember2021-09-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000935494us-gaap:CommonStockMember2020-12-310000935494us-gaap:AdditionalPaidInCapitalMember2020-12-310000935494us-gaap:RetainedEarningsMember2020-12-310000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000935494us-gaap:RetainedEarningsMember2021-01-012021-09-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000935494us-gaap:CommonStockMember2021-01-012021-09-300000935494us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000935494us-gaap:CommonStockMember2020-06-300000935494us-gaap:AdditionalPaidInCapitalMember2020-06-300000935494us-gaap:RetainedEarningsMember2020-06-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000009354942020-06-300000935494us-gaap:RetainedEarningsMember2020-07-012020-09-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000935494us-gaap:CommonStockMember2020-07-012020-09-300000935494us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000935494us-gaap:CommonStockMember2020-09-300000935494us-gaap:AdditionalPaidInCapitalMember2020-09-300000935494us-gaap:RetainedEarningsMember2020-09-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000935494us-gaap:CommonStockMember2019-12-310000935494us-gaap:AdditionalPaidInCapitalMember2019-12-310000935494us-gaap:RetainedEarningsMember2019-12-310000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000935494us-gaap:RetainedEarningsMember2020-01-012020-09-300000935494us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000935494us-gaap:CommonStockMember2020-01-012020-09-300000935494us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000935494us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembernati:AWRCorporationMember2020-01-150000935494us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembernati:AWRCorporationMember2020-01-152020-01-150000935494us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000935494us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300000935494us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000935494us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AmericasMember2021-07-012021-09-300000935494srt:AmericasMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300000935494srt:AmericasMember2021-07-012021-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AmericasMember2020-07-012020-09-300000935494srt:AmericasMemberus-gaap:TransferredOverTimeMember2020-07-012020-09-300000935494srt:AmericasMember2020-07-012020-09-300000935494us-gaap:TransferredAtPointInTimeMemberus-gaap:EMEAMember2021-07-012021-09-300000935494us-gaap:TransferredOverTimeMemberus-gaap:EMEAMember2021-07-012021-09-300000935494us-gaap:EMEAMember2021-07-012021-09-300000935494us-gaap:TransferredAtPointInTimeMemberus-gaap:EMEAMember2020-07-012020-09-300000935494us-gaap:TransferredOverTimeMemberus-gaap:EMEAMember2020-07-012020-09-300000935494us-gaap:EMEAMember2020-07-012020-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AsiaPacificMember2021-07-012021-09-300000935494srt:AsiaPacificMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300000935494srt:AsiaPacificMember2021-07-012021-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AsiaPacificMember2020-07-012020-09-300000935494srt:AsiaPacificMemberus-gaap:TransferredOverTimeMember2020-07-012020-09-300000935494srt:AsiaPacificMember2020-07-012020-09-300000935494us-gaap:TransferredAtPointInTimeMember2021-07-012021-09-300000935494us-gaap:TransferredOverTimeMember2021-07-012021-09-300000935494us-gaap:TransferredAtPointInTimeMember2020-07-012020-09-300000935494us-gaap:TransferredOverTimeMember2020-07-012020-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AmericasMember2021-01-012021-09-300000935494srt:AmericasMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300000935494srt:AmericasMember2021-01-012021-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AmericasMember2020-01-012020-09-300000935494srt:AmericasMemberus-gaap:TransferredOverTimeMember2020-01-012020-09-300000935494srt:AmericasMember2020-01-012020-09-300000935494us-gaap:TransferredAtPointInTimeMemberus-gaap:EMEAMember2021-01-012021-09-300000935494us-gaap:TransferredOverTimeMemberus-gaap:EMEAMember2021-01-012021-09-300000935494us-gaap:EMEAMember2021-01-012021-09-300000935494us-gaap:TransferredAtPointInTimeMemberus-gaap:EMEAMember2020-01-012020-09-300000935494us-gaap:TransferredOverTimeMemberus-gaap:EMEAMember2020-01-012020-09-300000935494us-gaap:EMEAMember2020-01-012020-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AsiaPacificMember2021-01-012021-09-300000935494srt:AsiaPacificMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300000935494srt:AsiaPacificMember2021-01-012021-09-300000935494us-gaap:TransferredAtPointInTimeMembersrt:AsiaPacificMember2020-01-012020-09-300000935494srt:AsiaPacificMemberus-gaap:TransferredOverTimeMember2020-01-012020-09-300000935494srt:AsiaPacificMember2020-01-012020-09-300000935494us-gaap:TransferredAtPointInTimeMember2021-01-012021-09-300000935494us-gaap:TransferredOverTimeMember2021-01-012021-09-300000935494us-gaap:TransferredAtPointInTimeMember2020-01-012020-09-300000935494us-gaap:TransferredOverTimeMember2020-01-012020-09-30xbrli:pure00009354942021-10-012021-09-3000009354942022-01-012021-09-3000009354942023-01-012021-09-300000935494us-gaap:DomesticCorporateDebtSecuritiesMember2021-09-300000935494us-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000935494us-gaap:CorporateDebtSecuritiesMember2021-09-3000009354942021-01-012021-03-310000935494us-gaap:MoneyMarketFundsMember2021-09-300000935494us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-300000935494us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-09-300000935494us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-09-300000935494us-gaap:FairValueInputsLevel1Member2021-09-300000935494us-gaap:FairValueInputsLevel2Member2021-09-300000935494us-gaap:FairValueInputsLevel3Member2021-09-300000935494us-gaap:MoneyMarketFundsMember2020-12-310000935494us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310000935494us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310000935494us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2020-12-310000935494us-gaap:CorporateDebtSecuritiesMember2020-12-310000935494us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000935494us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000935494us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000935494us-gaap:FairValueInputsLevel1Member2020-12-310000935494us-gaap:FairValueInputsLevel2Member2020-12-310000935494us-gaap:FairValueInputsLevel3Member2020-12-31nati:country0000935494nati:NonAmericasMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000935494nati:NonAmericasMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-07-012020-09-300000935494nati:NonAmericasMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300000935494nati:NonAmericasMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-300000935494srt:MaximumMemberus-gaap:ForwardContractsMember2021-09-300000935494us-gaap:ForwardContractsMember2021-01-012021-09-300000935494currency:GBP2021-09-300000935494currency:GBP2020-12-310000935494currency:CNY2021-09-300000935494currency:CNY2020-12-310000935494currency:EUR2021-09-300000935494currency:EUR2020-12-310000935494currency:HUF2021-09-300000935494currency:HUF2020-12-310000935494currency:JPY2021-09-300000935494currency:JPY2020-12-310000935494currency:KRW2021-09-300000935494currency:KRW2020-12-310000935494currency:MYR2021-09-300000935494currency:MYR2020-12-3100009354942020-01-012020-12-310000935494us-gaap:SalesMemberus-gaap:ForwardContractsMember2021-01-012021-09-300000935494us-gaap:ForwardContractsMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000935494us-gaap:OperatingExpenseMemberus-gaap:ForwardContractsMember2021-01-012021-09-300000935494srt:MaximumMembernati:OtherDerivativesMember2021-09-300000935494srt:MaximumMembernati:OtherDerivativesMember2021-01-012021-09-300000935494nati:OtherDerivativesMember2021-09-300000935494nati:OtherDerivativesMember2020-12-310000935494nati:ForeignExchangeContractShortTermMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000935494nati:ForeignExchangeContractShortTermMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000935494us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMembernati:ForeignExchangeContractLongTermMember2021-09-300000935494us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMembernati:ForeignExchangeContractLongTermMember2020-12-310000935494us-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000935494nati:ForeignExchangeContractShortTermMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2021-09-300000935494nati:ForeignExchangeContractShortTermMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2020-12-310000935494us-gaap:NondesignatedMember2021-09-300000935494us-gaap:NondesignatedMember2020-12-310000935494nati:ForeignExchangeContractShortTermMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000935494nati:ForeignExchangeContractShortTermMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000935494us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMembernati:ForeignExchangeContractLongTermMember2021-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMembernati:ForeignExchangeContractLongTermMember2020-12-310000935494nati:ForeignExchangeContractShortTermMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-09-300000935494nati:ForeignExchangeContractShortTermMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2020-12-310000935494us-gaap:DesignatedAsHedgingInstrumentMembernati:ForeignExchangeForwardAMember2021-07-012021-09-300000935494us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000935494nati:ForeignExchangeForwardBMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000935494us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000935494nati:ForeignExchangeForwardCMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000935494us-gaap:OperatingExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMembernati:ForeignExchangeForwardAMember2020-07-012020-09-300000935494us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300000935494nati:ForeignExchangeForwardBMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300000935494us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300000935494nati:ForeignExchangeForwardCMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300000935494us-gaap:OperatingExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300000935494us-gaap:NondesignatedMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeForwardMember2021-07-012021-09-300000935494us-gaap:NondesignatedMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeForwardMember2020-07-012020-09-300000935494us-gaap:NondesignatedMember2021-07-012021-09-300000935494us-gaap:NondesignatedMember2020-07-012020-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMembernati:ForeignExchangeForwardAMember2021-01-012021-09-300000935494us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000935494nati:ForeignExchangeForwardBMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000935494us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000935494nati:ForeignExchangeForwardCMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000935494us-gaap:OperatingExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMembernati:ForeignExchangeForwardAMember2020-01-012020-09-300000935494us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000935494nati:ForeignExchangeForwardBMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000935494us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000935494nati:ForeignExchangeForwardCMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000935494us-gaap:OperatingExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000935494us-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000935494us-gaap:NondesignatedMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-09-300000935494us-gaap:NondesignatedMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeForwardMember2020-01-012020-09-300000935494us-gaap:NondesignatedMember2021-01-012021-09-300000935494us-gaap:NondesignatedMember2020-01-012020-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMember2021-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-310000935494us-gaap:DevelopedTechnologyRightsMember2021-09-300000935494us-gaap:DevelopedTechnologyRightsMember2020-12-310000935494us-gaap:CustomerRelationshipsMember2021-09-300000935494us-gaap:CustomerRelationshipsMember2020-12-310000935494us-gaap:PatentsMember2021-09-300000935494us-gaap:PatentsMember2020-12-310000935494us-gaap:OtherIntangibleAssetsMember2021-09-300000935494us-gaap:OtherIntangibleAssetsMember2020-12-310000935494us-gaap:ComputerSoftwareIntangibleAssetMember2021-07-012021-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMember2020-07-012020-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMember2021-01-012021-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMember2020-01-012020-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MinimumMember2021-01-012021-09-300000935494us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2021-01-012021-09-300000935494us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2021-01-012021-09-300000935494srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember2021-01-012021-09-300000935494us-gaap:PatentsMembersrt:MinimumMember2021-01-012021-09-300000935494srt:MaximumMemberus-gaap:PatentsMember2021-01-012021-09-30nati:segment0000935494srt:MinimumMember2021-09-300000935494srt:MaximumMember2021-09-300000935494country:HU2021-01-012021-09-300000935494country:HU2021-07-012021-09-300000935494country:HU2020-07-012020-09-300000935494country:HU2020-01-012020-09-300000935494country:MY2021-07-012021-09-300000935494country:MY2021-01-012021-09-300000935494country:MY2020-07-012020-09-300000935494country:MY2020-01-012020-09-300000935494us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000935494us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000935494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000935494us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000935494us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000935494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000935494us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000935494us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300000935494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000935494us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000935494us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000935494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000935494us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300000935494us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300000935494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000935494us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000935494us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300000935494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300000935494nati:IncentivePlanTwoThousandAndFiveMember2005-05-100000935494us-gaap:ShareBasedCompensationAwardTrancheOneMembernati:IncentivePlanTwoThousandAndFiveMember2005-05-102005-05-100000935494nati:IncentivePlanTwoThousandAndFiveMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2005-05-102005-05-100000935494us-gaap:ShareBasedCompensationAwardTrancheThreeMembernati:IncentivePlanTwoThousandAndFiveMember2005-05-102005-05-100000935494nati:IncentivePlanTwoThousandAndFiveMember2005-05-102005-05-100000935494nati:IncentivePlanTwoThousandAndFiveMember2010-05-110000935494nati:IncentivePlanTwoThousandAndTenMember2010-05-110000935494nati:IncentivePlan1994And2005Member2010-05-110000935494us-gaap:ShareBasedCompensationAwardTrancheOneMembernati:IncentivePlanTwoThousandAndTenMember2010-05-112010-05-110000935494nati:IncentivePlanTwoThousandAndTenMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2010-05-112010-05-110000935494us-gaap:ShareBasedCompensationAwardTrancheThreeMembernati:IncentivePlanTwoThousandAndTenMember2010-05-112010-05-110000935494nati:IncentivePlanTwoThousandAndTenMember2015-05-120000935494nati:IncentivePlan2015Member2015-05-120000935494us-gaap:ShareBasedCompensationAwardTrancheOneMembernati:IncentivePlan2015Member2015-05-122015-05-120000935494nati:IncentivePlan2015Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2015-05-122015-05-120000935494us-gaap:ShareBasedCompensationAwardTrancheThreeMembernati:IncentivePlan2015Member2015-05-122015-05-120000935494nati:IncentivePlan2015Membernati:ShareBasedCompensationAwardTrancheFourMember2015-05-122015-05-120000935494nati:IncentivePlan2015Member2020-05-050000935494nati:IncentivePlan2020Member2020-05-050000935494us-gaap:ShareBasedCompensationAwardTrancheOneMembernati:IncentivePlan2020Member2020-05-052020-05-050000935494nati:IncentivePlan2020Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-05-052020-05-050000935494us-gaap:ShareBasedCompensationAwardTrancheThreeMembernati:IncentivePlan2020Member2020-05-052020-05-050000935494nati:ShareBasedCompensationAwardTrancheFourMembernati:IncentivePlan2020Member2020-05-052020-05-050000935494nati:IncentivePlan2020Member2021-09-300000935494us-gaap:PerformanceSharesMember2021-01-012021-09-300000935494us-gaap:PerformanceSharesMember2020-01-012020-09-300000935494us-gaap:PerformanceSharesMember2021-01-012021-01-010000935494us-gaap:PerformanceSharesMember2020-01-012020-01-010000935494srt:MinimumMember2021-01-012021-09-30nati:simulation0000935494us-gaap:PerformanceSharesMember2021-09-300000935494us-gaap:PerformanceSharesMember2020-09-300000935494nati:EmployeeStockPurchasePlanMember2021-09-300000935494nati:EmployeeStockPurchasePlanMember2019-05-140000935494nati:EmployeeStockPurchasePlanMember2021-01-012021-09-3000009354942019-10-230000935494srt:MaximumMember2021-01-012021-09-30nati:region0000935494country:US2021-07-012021-09-300000935494country:CN2021-07-012021-09-300000935494nati:RestOfTheWorldMember2021-07-012021-09-300000935494country:US2020-07-012020-09-300000935494country:CN2020-07-012020-09-300000935494nati:RestOfTheWorldMember2020-07-012020-09-300000935494country:US2021-01-012021-09-300000935494country:CN2021-01-012021-09-300000935494nati:RestOfTheWorldMember2021-01-012021-09-300000935494country:US2020-01-012020-09-300000935494country:CN2020-01-012020-09-300000935494nati:RestOfTheWorldMember2020-01-012020-09-300000935494country:US2021-09-300000935494country:HU2021-09-300000935494country:MY2021-09-300000935494nati:RestOfTheWorldMember2021-09-300000935494country:US2020-12-310000935494country:HU2020-12-310000935494country:MY2020-12-310000935494nati:RestOfTheWorldMember2020-12-310000935494nati:CreditAgreementMembernati:SecuredRevolvingLoanFacilityMember2021-06-180000935494us-gaap:RevolvingCreditFacilityMembernati:WellsFargoTermLoanMemberus-gaap:LineOfCreditMember2021-06-180000935494us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMembernati:CreditAgreementMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMembernati:CreditAgreementMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMembernati:CreditAgreementMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMembernati:CreditAgreementMember2021-06-182021-06-180000935494nati:CreditAgreementMember2021-06-180000935494us-gaap:RevolvingCreditFacilityMembersrt:MinimumMembernati:CreditAgreementMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMembersrt:MaximumMembernati:CreditAgreementMember2021-06-182021-06-180000935494us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMembernati:CreditAgreementMember2021-06-180000935494nati:WellsFargoTermLoanMember2020-12-310000935494nati:WellsFargoTermLoanMember2021-09-300000935494nati:WellsFargoRevolvingCreditLoanMember2021-09-300000935494nati:WellsFargoRevolvingCreditLoanMember2020-12-310000935494us-gaap:CostOfSalesMember2021-07-012021-09-300000935494us-gaap:CostOfSalesMember2020-07-012020-09-300000935494us-gaap:CostOfSalesMember2021-01-012021-09-300000935494us-gaap:CostOfSalesMember2020-01-012020-09-300000935494us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000935494us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000935494us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000935494us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000935494us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300000935494us-gaap:SellingAndMarketingExpenseMember2020-07-012020-09-300000935494us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300000935494us-gaap:SellingAndMarketingExpenseMember2020-01-012020-09-300000935494us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300000935494us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300000935494us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300000935494us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300000935494us-gaap:EmployeeSeveranceMember2021-09-300000935494nati:OptimalPlusLtdMember2020-07-020000935494nati:WellsFargoSecuritiesLLCMembernati:SecuredTermLoanFacilityMemberus-gaap:LineOfCreditMember2020-06-302020-06-300000935494nati:OptimalPlusLtdMember2020-12-310000935494nati:OptimalPlusLtdMember2020-07-022020-07-020000935494nati:OptimalPlusLtdMemberus-gaap:CustomerRelationshipsMember2020-07-022020-07-020000935494nati:OptimalPlusLtdMemberus-gaap:DevelopedTechnologyRightsMember2020-07-022020-07-020000935494us-gaap:InProcessResearchAndDevelopmentMembernati:OptimalPlusLtdMember2020-07-022020-07-020000935494nati:OptimalPlusLtdMemberus-gaap:OtherIntangibleAssetsMember2020-07-022020-07-020000935494nati:OptimalPlusLtdMembersrt:MinimumMemberus-gaap:OtherIntangibleAssetsMember2020-07-022020-07-020000935494srt:MaximumMembernati:OptimalPlusLtdMemberus-gaap:OtherIntangibleAssetsMember2020-07-022020-07-020000935494nati:OptimalPlusLtdMember2020-07-012020-09-300000935494nati:OptimalPlusLtdMember2020-01-012020-09-300000935494nati:OtherAcquisitionsMember2021-04-012021-06-300000935494nati:OtherAcquisitionsMember2021-06-300000935494us-gaap:SubsequentEventMember2021-10-192021-10-190000935494us-gaap:SubsequentEventMembernati:CorporationSpecializingInHighPowerTestAndMeasurementApplicationsMember2021-10-192021-10-190000935494us-gaap:SubsequentEventMembernati:CreditAgreementMembernati:SecuredRevolvingLoanFacilityMember2021-10-192021-10-190000935494us-gaap:SubsequentEventMembersrt:MinimumMember2021-10-260000935494us-gaap:SubsequentEventMembersrt:MaximumMember2021-10-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended: September 30, 2021

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ________________ to ________________

Commission file number: 000-25426

NATIONAL INSTRUMENTS CORPORATION

(Exact name of registrant as specified in its charter)


Delaware						74-1871327
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

11500 North MoPac Expressway
Austin,						78759
Texas
(Address of principal executive offices)						(Zip code)

Registrant's telephone number, including area code: (512) 683-0100

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of exchange on which registered
Common Stock, $0.01 par value	NATI	Nasdaq Stock Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.


Class			Outstanding at October 28, 2021
Common Stock, $0.01 par value			131,881,802

NATIONAL INSTRUMENTS CORPORATION

INDEX


PART I. FINANCIAL INFORMATION		Page No.

Item 1	Financial Statements:

	Consolidated Balance Sheets
	September 30, 2021 (unaudited) and December 31, 2020	3

	Consolidated Statements of Income
	(unaudited) for the three and nine months ended September 30, 2021 and 2020	4

	Consolidated Statements of Comprehensive Income
	(unaudited) for the three and nine months ended September 30, 2021 and 2020	5

	Consolidated Statements of Cash Flows
	(unaudited) for the nine months ended September 30, 2021 and 2020	6

	Consolidated Statements of Stockholders' Equity
	(unaudited) for the three and nine months ended September 30, 2021 and 2020	7

	Notes to Consolidated Financial Statements	9

Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	33

Item 3	Quantitative and Qualitative Disclosures about Market Risk	49

Item 4	Controls and Procedures	50


PART II. OTHER INFORMATION

Item 1	Legal Proceedings	50

Item 1A	Risk Factors	50

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	52

Item 3	Defaults Upon Senior Securities	52

Item 4	Mine Safety Disclosures	52

Item 5	Other Information	52

Item 6	Exhibits	53

	Signatures and Certifications	54

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

NATIONAL INSTRUMENTS CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)


	September 30,		December 31,
	2021		2020
Assets	(unaudited)
Cash and cash equivalents	$	230,697	$	260,232
Short-term investments	—		59,923
Accounts receivable, net	279,196		266,869
Inventories, net	236,733		194,012
Prepaid expenses and other current assets	89,152		68,470
Total current assets	835,778		849,506
Property and equipment, net	248,712		254,399
Goodwill	480,489		467,547
Intangible assets, net	136,938		172,719
Operating lease right-of-use assets	56,644		67,674

Other long-term assets	79,850		72,643
Total assets	$	1,838,411	$	1,884,488
Liabilities and stockholders' equity
Accounts payable and accrued expenses	$	63,568	$	51,124
Accrued compensation	87,802		87,068
Deferred revenue - current	120,762		132,151
Operating lease liabilities - current	12,360		15,801
Other taxes payable	43,673		48,129
Debt, current	—		5,000
Other current liabilities	25,162		42,578
Total current liabilities	353,327		381,851

Deferred income taxes	26,023		25,288
Income tax payable - non-current	54,195		61,623
Deferred revenue - non-current	32,278		36,335
Operating lease liabilities - non-current	29,206		35,854
Debt, non-current	100,000		92,036
Other long-term liabilities	16,910		26,630
Total liabilities	611,939		659,617
Commitments and contingencies
Stockholders' equity:
Preferred stock: par value $0.01; 5,000,000 shares authorized; none issued and outstanding	—		—
Common stock: par value $0.01; 360,000,000 shares authorized; 132,622,234 shares and 131,246,615 shares issued and outstanding, respectively	1,326		1,312
Additional paid-in capital	1,109,918		1,033,284
Retained earnings	132,404		211,101
Accumulated other comprehensive loss	(17,176)		(20,826)
Total stockholders’ equity	1,226,472		1,224,871
Total liabilities and stockholders’ equity	$	1,838,411	$	1,884,488

The accompanying notes are an integral part of the financial statements.

NATIONAL INSTRUMENTS CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

(unaudited)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020

Net sales:
Product	$	325,724	$	269,651	$	927,307	$	809,890
Software maintenance	41,438		38,473		121,733		108,944
Total net sales	367,162		308,124		1,049,040		918,834

Cost of sales:
Product	99,072		88,370		286,485		254,236
Software maintenance	3,643		3,893		10,882		7,689
Total cost of sales	102,715		92,263		297,367		261,925

Gross profit	264,447		215,861		751,673		656,909

Operating expenses:
Sales and marketing	117,065		109,774		345,048		330,939
Research and development	82,165		70,802		243,685		206,648
General and administrative	31,037		37,431		94,672		92,980

Total operating expenses	230,267		218,007		683,405		630,567
Gain on sale of business/assets	—		—		—		159,753
Operating income	34,180		(2,146)		68,268		186,095

Other expense	(1,820)		(2,001)		(9,851)		(2,584)
Income before income taxes	32,360		(4,147)		58,417		183,511
Provision for income taxes	5,183		475		9,438		44,588

Net income (loss)	$	27,177	$	(4,622)	$	48,979	$	138,923

Basic earnings per share	$	0.20	$	(0.04)	$	0.37	$	1.06

Weighted average shares outstanding - basic	133,031		131,419		132,657		131,017

Diluted earnings per share	$	0.20	$	(0.04)	$	0.37	$	1.06

Weighted average shares outstanding - diluted	133,686		131,419		133,829		131,671

Dividends declared per share	$	0.27	$	0.26	$	0.81	$	0.78

The accompanying notes are an integral part of these financial statements.

NATIONAL INSTRUMENTS CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020

Net income (loss)	$	27,177	$	(4,622)	$	48,979	$	138,923
Other comprehensive (loss) income, before tax and net of reclassification adjustments:
Foreign currency translation adjustment	(5,675)		8,483		(10,585)		6,507
Unrealized loss on securities available-for-sale	(21)		(163)		(162)		(317)
Unrealized gain (loss) on derivative instruments	4,243		(9,530)		18,605		(10,128)
Other comprehensive income (loss), before tax	(1,453)		(1,210)		7,858		(3,938)
Tax expense (benefit) related to items of other comprehensive income	948		(2,335)		4,208		(2,268)
Other comprehensive (loss) income, net of tax	(2,401)		1,125		3,650		(1,670)
Comprehensive income (loss)	$	24,776	$	(3,497)	$	52,629	$	137,253

The accompanying notes are an integral part of these financial statements.

NATIONAL INSTRUMENTS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)


	Nine Months Ended
	September 30,
	2021		2020
Cash flow from operating activities:
Net income	$	48,979	$	138,923
Adjustments to reconcile net income to net cash provided by operating activities:
Disposal gain on sale of business/assets	—		(159,753)
Depreciation and amortization	73,418		61,228
Stock-based compensation	56,064		42,556
Loss from equity-method investees	5,082		2,559

Deferred income taxes	(2,030)		(932)
Changes in operating assets and liabilities	(95,477)		24,203
Net cash provided by operating activities	86,036		108,784

Cash flow from investing activities:
Acquisitions, net of cash received	(19,784)		(334,981)
Capital expenditures	(26,147)		(36,573)
Proceeds from sale of assets/business, net of cash divested	—		160,266

Capitalization of internally developed software	(1,246)		(2,806)
Additions to other intangibles	(2,317)		(1,045)

Payments to acquire equity-method investments	(15,753)		(7,502)
Purchases of short-term investments	—		(206,330)
Sales and maturities of short-term investments	59,714		351,597
Net cash used in investing activities	(5,533)		(77,374)

Cash flow from financing activities:
Proceeds from revolving line of credit	100,000		20,000


Proceeds from term loan	—		70,000
Payments on term loan	(98,750)		(875)
Debt issuance costs	(1,993)		(1,480)
Proceeds from issuance of common stock	25,438		24,971
Repurchase of common stock	(25,000)		(39,244)
Dividends paid	(107,397)		(102,396)
Net cash used in financing activities	(107,702)		(29,024)

Effect of exchange rate changes on cash	(2,336)		317

Net change in cash and cash equivalents	(29,535)		2,703
Cash and cash equivalents at beginning of period	260,232		194,616
Cash and cash equivalents at end of period	$	230,697	$	197,319

The accompanying notes are an integral part of these financial statements.

NATIONAL INSTRUMENTS CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data and per share data)

(unaudited)


	September 30, 2021
	(Unaudited)
	Common Stock Shares	Common Stock Amount		Additional-Paid in Capital		Retained Earnings		Accumulated Other Comprehensive Income/(Loss)		Total Stockholders' Equity
Balance at June 30, 2021	132,980,932	$	1,330	$	1,087,622	$	161,475	$	(14,775)	$	1,235,652
Net income	—	—		—		27,177		—		27,177
Other comprehensive loss, net of tax	—	—		—		—		(2,401)		(2,401)
Issuance of common stock under employee plans	240,368	2		8,197		—		—		8,199
Stock-based compensation	—	—		18,814		—		—		18,814

Repurchase of common stock	(599,066)	(6)		(4,715)		(20,279)		—		(25,000)


Dividends paid (1)	—	—		—		(35,969)		—		(35,969)
Balance at September 30, 2021	132,622,234	1,326		1,109,918		132,404		(17,176)		1,226,472

	Common Stock Shares	Common Stock Amount		Additional-Paid in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
Balance at December 31, 2020	131,246,615	1,312		1,033,284		211,101		(20,826)		1,224,871
Net income	—	—		—		48,979		—		48,979
Other comprehensive gain, net of tax	—	—		—		—		3,650		3,650
Issuance of common stock under employee plans	1,974,685	20		25,418		—		—		25,438
Stock-based compensation	—	—		55,931		—		—		55,931

Repurchase of common stock	(599,066)	(6)		(4,715)		(20,279)		—		(25,000)


Dividends paid (1)	—	—		—		(107,397)		—		(107,397)
Balance at September 30, 2021	132,622,234	$	1,326	$	1,109,918	$	132,404	$	(17,176)	$	1,226,472

(1) Cash dividends declared per share of common stock were $0.27 for the three months ended September 30, 2021, and $0.81 for the nine months ended September 30, 2021.

The accompanying notes are an integral part of these financial statements.


	September 30, 2020
	(Unaudited)
	Common Stock Shares	Common Stock Amount		Additional-Paid in Capital		Retained Earnings		Accumulated Other Comprehensive Income/(Loss)		Total Stockholders' Equity
Balance at June 30, 2020	131,436,108	$	1,314	$	993,058	$	299,132	$	(23,865)	$	1,269,639
Net loss	—	—		—		(4,622)		—		(4,622)
Other comprehensive gain, net of tax	—	—		—		—		1,125		1,125
Issuance of common stock under employee plans	256,034	2		7,715		—		—		7,717
Stock-based compensation	—	—		15,142		—		—		15,142

Repurchase of common stock	(446,502)	(4)		(3,259)		(12,300)		—		(15,563)

Dividends paid (1)	—	—		—		(34,240)		—		(34,240)
Balance at September 30, 2020	131,245,640	1,312		1,012,656		247,970		(22,740)		1,239,198

	Common Stock Shares	Common Stock Amount		Additional-Paid in Capital		Retained Earnings		Accumulated Other Comprehensive Income/(Loss)		Total Stockholders' Equity
Balance at December 31, 2019	130,504,535	1,305		953,578		242,537		(21,070)		1,176,350
Net income	—	—		—		138,923		—		138,923
Other comprehensive loss, net of tax	—	—		—		—		(1,670)		(1,670)
Issuance of common stock under employee plans	1,855,806	18		24,953		—		—		24,971
Stock-based compensation	—	—		42,264		—		—		42,264

Repurchase of common stock	(1,114,701)	(11)		(8,139)		(31,094)		—		(39,244)

Dividends paid (1)	—	—		—		(102,396)		—		(102,396)
Balance at September 30, 2020	131,245,640	$	1,312	$	1,012,656	$	247,970	$	(22,740)	$	1,239,198

(1) Cash dividends declared per share of common stock were $0.26 for the three months ended September 30, 2020, and $0.78 for the nine months ended September 30, 2020.

The accompanying notes are an integral part of these financial statements.

NATIONAL INSTRUMENTS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – Basis of presentation

The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2020, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 23, 2021 (the "Form 10-K"). In our opinion, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly our financial position at September 30, 2021 and December 31, 2020, the results of our operations and comprehensive income for three and nine months ended September 30, 2021 and 2020, our cash flows for the nine months ended September 30, 2021 and 2020 and our statement of stockholders' equity for the three and nine months ended September 30, 2021 and 2020. Our operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform to the current period presentation.

Recently Adopted Accounting Pronouncements

Clarification of Equity Method Transition

In January 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815,” which clarifies the interaction of the accounting for equity investments under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted ASU 2020-01 on January 1, 2021, and the new standard did not have a material impact on our consolidated financial statements and related disclosures.

Recently Issued Accounting Pronouncements

Although there are several other accounting pronouncements recently issued by the FASB, we do not expect the adoption of any of these accounting pronouncements had or will have a material impact on our consolidated financial statements.

Summary of Significant Accounting Policies

There were no changes in our significant accounting policies during the three and nine months ended September 30, 2021 compared to the significant accounting policies described in our Form 10-K.

Divestitures

AWR

On January 15, 2020, we completed the sale of our AWR Corporation subsidiary ("AWR") for approximately $161 million. We recognized a gain of approximately $160 million on the sale. The gain is included within "Gain on sale of business/assets" in the consolidated statements of income, which also included approximately $1 million of transaction costs.

The divestiture of AWR resulted in the derecognition of the following assets and liabilities:


(In thousands)
Cash	$	1,027
Accounts receivable, net	7,233
Prepaid and other current assets	283
Goodwill	7,221
Other non-current assets	556
Total Assets	16,320

Deferred revenue	15,296
Other current liabilities	940
Cumulative translation adjustment	(660)
Total liabilities and stockholders' equity	15,576

Total assets divested, net (including cash)	$	744

Other (Expense) Income

Other expense, net consisted of the following amounts:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Interest income	$	56	$	414	$	330	$	3,724
Interest expense	(657)		(973)		(2,584)		(1,115)
Gain (loss) from equity-method investments	278		(627)		(5,082)		(2,559)
Net foreign exchange loss	(1,226)		(676)		(2,681)		(2,019)
Other	(271)		(139)		166		(615)
Other expense, net	$	(1,820)	$	(2,001)	$	(9,851)	$	(2,584)

Earnings Per Share

Basic earnings per share (“EPS”) is computed by dividing net income by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which includes restricted stock units ("RSUs"), is computed using the treasury stock method. The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands):


	Three Months Ended September 30,		Nine Months Ended September 30,
	(Unaudited)		(Unaudited)
	2021	2020	2021	2020
Weighted average shares outstanding-basic	133,031	131,419	132,657	131,017
Plus: Common share equivalents
RSUs	655	—	1,172	654
Weighted average shares outstanding-diluted	133,686	131,419	133,829	131,671

Shares issuable upon vesting of RSU awards of 143,000 shares and 3,490,700 shares for the three months ended September 30, 2021 and 2020, respectively, and 123,000 shares and 276,000 shares for the nine months ended September 30, 2021 and 2020, respectively, were excluded in the computations of diluted EPS because the effect of including the stock awards would have been anti-dilutive.

Other Current Liabilities

Other current liabilities on our consolidated balance sheet includes the following amounts:


	As of September 30, 2021		As of December 31,
(In thousands)	(unaudited)		2020
Income taxes payable - current	$	2,590	$	13,720
Hedge payable - current	6,058		13,031
Other	16,514		15,827
Total	$	25,162	$	42,578

Note 2 - Revenue

Revenue Recognition

Revenue is recognized upon transfer of control of the promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of our products or services, which are generally capable of being distinct and accounted for as separate performance obligations. Revenue is recognized net of allowances for returns and any taxes collected from customers, which are subsequently remitted to governmental authorities.

Disaggregation of Revenues

We disaggregate revenue from contracts with customers based on the timing of transfer of goods or services to customers (point-in-time or over time) and geographic region based on the billing location of the customer. We sell our products in the following three geographic regions: the Americas; Europe, Middle East and Africa region ("EMEA"); and Asia-Pacific region ("APAC").

Total net sales based on the disaggregation criteria described above are as follows:


			Three Months Ended September 30,
(In thousands)			(Unaudited)
	2021						2020

Net sales:	Point-in-Time(1)		Over Time		Total		Point-in-Time(1)		Over Time		Total
Americas	$	125,069	$	23,835	$	148,904	$	107,808	$	19,241	$	127,049
EMEA	72,430		22,433		94,863		57,988		20,551		78,539
APAC	112,931		10,464		123,395		92,050		10,486		102,536
Total net sales(1)	$	310,430	$	56,732	$	367,162	$	257,846	$	50,278	$	308,124
(1) Net sales contains hedging gains and losses, which do not represent revenues recognized from customers. See Note 5 - Derivative instruments and hedging activities of Notes to Consolidated Financial Statements for more information on the impact of our hedging activities on our results of operations.


			Nine Months Ended September 30,
(In thousands)			(Unaudited)
	2021						2020

Net sales:	Point-in-Time(1)		Over Time		Total		Point-in-Time(1)		Over Time		Total
Americas	$	341,870	$	68,436	$	410,306	$	316,220	$	57,554	$	373,774
EMEA	204,786		64,769		269,555		181,330		58,594		239,924
APAC	337,455		31,724		369,179		274,341		30,795		305,136
Total net sales(1)	$	884,111	$	164,929	$	1,049,040	$	771,891	$	146,943	$	918,834
(1) Net sales contains hedging gains and losses, which do not represent revenues recognized from customers. See Note 5 - Derivative instruments and hedging activities of Notes to Consolidated Financial Statements for more information on the impact of our hedging activities on our results of operations.

Information about Contract Balances

Amounts collected in advance of services being provided are accounted for as deferred revenue. Nearly all of our deferred revenue balance is related to extended hardware and software maintenance contracts. Payment terms and conditions vary by contract type, although payment is typically due within 30 to 90 days of contract inception. In instances where the timing of revenue recognition differs from the timing of invoicing, we have determined our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simplified and predictable ways of purchasing our products and services, not to receive financing from our customers, such as invoicing at the beginning of a subscription term with a portion of the revenue recognized ratably over the contract period, or to provide customers with financing, such as multi-year on-premises licenses that are invoiced annually with revenue recognized upfront.

Changes in deferred revenue, current and non-current, during the nine months ended September 30, 2021 were as follows:



(In thousands)	Amount
Balance as of December 31, 2020	$	168,486
Deferral of revenue billed in current period, net of recognition	104,092
Recognition of revenue deferred in prior periods	(115,999)

Foreign currency translation impact	(3,539)
Balance as of September 30, 2021 (unaudited)	$	153,040

For the nine months ended September 30, 2021, revenue recognized from performance obligations satisfied in prior periods (for example, due to changes in transaction price) was not material. Amounts recognized as revenue in excess of amounts billed are recorded as unbilled receivables. Unbilled receivables which are anticipated to be invoiced in the next twelve months are included in "Other current assets" on the consolidated balance sheet. Based on the nature of our contracts with customers, we do not typically recognize unbilled receivables related to revenues recognized in excess of amounts billed. For the nine months ended September 30, 2021, the amounts recorded that were related to unbilled receivables were not material.

Unsatisfied Performance Obligations

Revenue expected to be recognized in any future period related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less and contracts where revenue is recognized as invoiced, was approximately $61 million as of September 30, 2021. Since we typically invoice customers at contract inception, this amount is included in our current and non-current deferred revenue balances. As of September 30, 2021, we expect to recognize approximately 14% of the revenue related to these unsatisfied performance obligations during the remainder of 2021, 45% during 2022, and 41% thereafter.

Assets Recognized from the Costs to Obtain a Contract with a Customer

We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. Capitalized incremental costs related to initial contracts and renewals are amortized over the same period because the commissions paid on both the initial contract and renewals are commensurate with one another. Total capitalized costs to obtain a contract were not material during the periods presented and are included in other long-term assets on our consolidated balance sheets.

Note 3 – Investments

The following tables summarize unrealized gains and losses related to our short-term investments designated as available-for-sale debt securities:

As of September 30, 2021

(In thousands)

(Unaudited)

Gross

Adjusted Cost

Unrealized Gain

Unrealized Loss

Fair Value

Corporate bonds

—

Total short-term investments

—


(In thousands)	As of December 31, 2020
			Gross		Gross
	Adjusted Cost		Unrealized Gain		Unrealized Loss		Fair Value
Corporate bonds	$	59,761	$	163	$	(1)	$	59,923

Total short-term investments	$	59,761	$	163	$	(1)	$	59,923

The following tables summarize the contractual maturities of our short-term investments designated as available-for-sale debt securities:

As of September 30, 2021

(In thousands)

(Unaudited)

Due in less than 1 year

Adjusted Cost

Fair Value

Corporate bonds

—

Total available-for-sale debt securities

—

Equity-Method Investments

The carrying value of our equity method investments was $33 million and $25 million as of September 30, 2021 and December 31, 2020, respectively. During the first quarter of 2021, we determined there was an other than temporary impairment for one of our equity-method investments, based on revised forecasts. We recorded a $3.5 million impairment loss related to this investment during the three months ended March 31, 2021. Our proportionate share of the income/(loss) from equity-method investments is included within "Other expense". Refer to Note 1 - Basis of Presentation of Notes to Consolidated Financial Statements for additional information on these amounts for the three and nine months ended September 30, 2021 and 2020.

Note 4 – Fair value measurements

We define fair value to be the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market that market participants may use when pricing the asset or liability.

We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value measurement is determined based on the lowest level input that is significant to the fair value measurement. The three values of the fair value hierarchy are the following:

Level 1 – Quoted prices in active markets for identical assets or liabilities

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 – Inputs that are not based on observable market data

Assets and liabilities measured at fair value on a recurring basis are summarized below:


	Fair Value Measurements at Reporting Date Using
(In thousands)	(Unaudited)
Description	September 30, 2021		Level 1		Level 2		Level 3
Assets
Cash and cash equivalents:
Money market funds	$	113,553	$	113,553	$	—	$	—


Other assets



Derivatives	10,453		—		10,453		—
Total Assets	$	124,006	$	113,553	$	10,453	$	—

Liabilities
Derivatives	$	(7,528)	$	—	$	(7,528)	$	—
Total Liabilities	$	(7,528)	$	—	$	(7,528)	$	—


(In thousands)	Fair Value Measurements at Reporting Date Using
Description	December 31, 2020		Level 1		Level 2		Level 3
Assets
Cash and cash equivalents:
Money market funds	$	145,466	$	145,466	$	—	$	—


Short-term investments available for sale:
Corporate bonds	59,923		—		59,923		—


Other assets
Derivatives	6,124		—		6,124		—
Total Assets	$	211,513	$	145,466	$	66,047	$	—

Liabilities
Derivatives	$	(19,359)	$	—	$	(19,359)	$	—
Total Liabilities	$	(19,359)	$	—	$	(19,359)	$	—

We value our available-for-sale short-term investments based on pricing from third party pricing vendors, who may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. We classify all of our fixed income available-for-sale securities as having Level 2 inputs. The valuation techniques used to measure the fair value of our financial instruments having Level 2 inputs were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models, such as discounted cash flow techniques. We believe all of these sources reflect the credit risk associated with each of our available-for-sale short-term investments. Short-term investments available-for-sale consists of debt securities issued by states of the U.S. and political subdivisions of the U.S., corporate debt securities and debt securities issued by U.S. government organizations and agencies. All of our short-term investments available-for-sale have contractual maturities of less than 60 months as of December 31, 2020.

Derivatives include foreign currency forward contracts. Our foreign currency forward contracts are valued using an income approach (Level 2) based on the spot rate less the contract rate multiplied by the notional amount. We consider counterparty credit risk in the valuation of our derivatives. However, counterparty credit risk did not impact the valuation of our derivatives during the nine months ended September 30, 2021. There were no transfers in or out of Level 1 or Level 2 during the nine months ended September 30, 2021.

We did not have any items that were measured at fair value on a nonrecurring basis at September 30, 2021 and December 31, 2020. The carrying value of net accounts receivable, accounts payable, and long-term debt contained in the consolidated balance sheets approximates fair value.

Note 5 – Derivative instruments and hedging activities

We recognize all of our derivative instruments as either assets or liabilities in our statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, we designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.

We have direct operations in approximately 40 countries. Sales outside of the Americas accounted for approximately 59% and 59% of our net sales during the three months ended September 30, 2021 and 2020, respectively, and approximately 61% and 59% during the nine months ended September 30, 2021 and 2020, respectively. Our activities expose us to a variety of market risks, including the effects of changes in foreign currency exchange rates. These financial risks are monitored and managed by us as an integral part of our overall risk management program.

We maintain a foreign currency risk management strategy that uses derivative instruments (foreign currency forward contracts) to help protect our earnings and cash flows from fluctuations caused by the volatility in currency exchange rates. Movements in foreign currency exchange rates pose a risk to our operations and competitive position, in that exchange rate changes may affect our profitability and cash flow, and the business or pricing strategies of our non-U.S. based competitors.

The vast majority of our foreign sales are denominated in the customers’ local currency. We use foreign currency forward contracts as hedges of forecasted sales that are denominated in foreign currencies and as hedges of foreign currency denominated financial assets or liabilities. These contracts are entered into to help protect against the risk that the eventual dollar-net-cash inflows resulting from such sales or firm commitments will be adversely affected by changes in exchange rates. We also use foreign currency forward contracts as hedges of forecasted expenses that are denominated in foreign currencies. These contracts are entered into to help protect against the risk that the eventual dollar-net-cash outflows resulting from foreign currency operating and cost of sales expenses will be adversely affected by changes in exchange rates.

We designate foreign currency forward contracts as cash flow hedges of forecasted net sales or forecasted expenses. In addition, we hedge our foreign currency denominated balance sheet exposures using foreign currency forward contracts that are not designated as hedging instruments. None of our derivative instruments contain a credit-risk-related contingent feature.

Cash flow hedges

To help protect against the reduction in value caused by a fluctuation in foreign currency exchange rates of forecasted foreign currency cash flows resulting from international sales over the next one to three years, we have instituted a foreign currency cash flow hedging program. We hedge portions of our forecasted net sales and forecasted expenses denominated in foreign currencies with forward contracts. For forward contracts, when the value of the dollar changes significantly against the foreign currencies, the change in the present value of future foreign currency cash flows may be offset by the change in the fair value of the forward contracts designated as hedges. We use foreign currency forward contracts for up to 100% of our forecasted exposures in selected currencies (primarily in Euro, Japanese yen, Hungarian forint, British pound, Malaysian ringgit, Korean won and Chinese yuan) and limit the duration of these contracts to 40 months or less.

For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of accumulated other comprehensive income ("OCI") and reclassified into earnings in the same line item (net sales, operating expenses, or cost of sales) associated with the forecasted transaction and in the same period or periods during which the hedged transaction affects earnings. Hedge effectiveness of foreign currency forwards designated as cash flow hedges is measured by comparing the hedging instrument’s cumulative change in fair value from inception to maturity to the forecasted transaction’s terminal value.

We held forward contracts designated as cash flow hedges with the following notional amounts:


(In thousands)	US Dollar Equivalent
	As of September 30, 2021		As of December 31,
	(Unaudited)		2020
British pound	$	31,445	$	25,133
Chinese yuan	96,205		45,553
Euro	176,759		219,115
Hungarian forint	64,928		82,429
Japanese yen	53,798		73,399
Korean won	24,092		22,301
Malaysian ringgit	34,536		36,249
Total forward contracts notional amount	$	481,763	$	504,179

The contracts in the foregoing table had contractual maturities of 27 months or less at September 30, 2021 and 36 months or less at December 31, 2020.

At September 30, 2021, we expect to reclassify $3.7 million of gains on derivative instruments from accumulated OCI to net sales during the next twelve months when the hedged international sales occur, $1.0 million of losses on derivative instruments from accumulated OCI to cost of sales during the next twelve months when the hedged cost of sales are incurred and $0.7 million of losses on derivative instruments from accumulated OCI to operating expenses during the next twelve months when the hedged operating expenses occur. Expected amounts are based on derivative valuations at September 30, 2021. Actual results may vary materially as a result of changes in the corresponding exchange rates subsequent to this date.

Other Derivatives

Other derivatives not designated as hedging instruments consist primarily of foreign currency forward contracts that we use to hedge our foreign denominated monetary assets and liabilities to help protect against the change in value caused by a fluctuation in foreign currency exchange rates. We typically attempt to hedge up to 90% of our outstanding foreign denominated net receivables or net payables and typically limit the duration of these foreign currency forward contracts to approximately 90 days or less. The gain or loss on the derivatives as well as the offsetting gain or loss on the hedge item attributable to the hedged risk is recognized in current earnings under the line item “Other expense.” As of September 30, 2021 and December 31, 2020, we held foreign currency forward contracts that were not designated as hedging instruments with a notional amount of $102 million and $89 million, respectively.

The following tables present the fair value of derivative instruments on our Consolidated Balance Sheets at September 30, 2021 and December 31, 2020, respectively.


	Asset Derivatives
		September 30, 2021		December 31, 2020
(In thousands)		(Unaudited)
	Balance Sheet Location	Fair Value		Fair Value

Derivatives designated as hedging instruments
Foreign exchange contracts - ST forwards	Prepaid expenses and other current assets	$	6,118	$	1,564
Foreign exchange contracts - LT forwards	Other long-term assets	3,915		3,117
Total derivatives designated as hedging instruments		$	10,033	$	4,681

Derivatives not designated as hedging instruments
Foreign exchange contracts - ST forwards	Prepaid expenses and other current assets	$	420	$	1,443
Total derivatives not designated as hedging instruments		$	420	$	1,443

Total derivatives		$	10,453	$	6,124


	Liability Derivatives
		September 30, 2021		December 31, 2020
(In thousands)		(Unaudited)
	Balance Sheet Location	Fair Value		Fair Value

Derivatives designated as hedging instruments
Foreign exchange contracts - ST forwards	Other current liabilities	$	(4,166)	$	(12,549)
Foreign exchange contracts - LT forwards	Other long-term liabilities	(1,470)		(6,328)
Total derivatives designated as hedging instruments		$	(5,636)	$	(18,877)

Derivatives not designated as hedging instruments
Foreign exchange contracts - ST forwards	Other current liabilities	$	(1,892)	$	(482)
Total derivatives not designated as hedging instruments		$	(1,892)	$	(482)

Total derivatives		$	(7,528)	$	(19,359)

The following tables present the effect of derivative instruments on our Consolidated Statements of Income for the three months ended September 30, 2021 and 2020, respectively:


September 30, 2021
(In thousands)
(Unaudited)
Derivatives in Cash Flow Hedging Relationship	Gain or (Loss) Recognized in OCI on Derivative		Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Gain or (Loss) Reclassified from Accumulated OCI into Income
Foreign exchange contracts - forwards	$	7,400	Net sales	$	(815)

Foreign exchange contracts - forwards	(1,869)		Cost of sales	(73)

Foreign exchange contracts - forwards	(1,288)		Operating expenses	(88)
Total	$	4,243		$	(976)


September 30, 2020
(In thousands)
(Unaudited)
Derivatives in Cash Flow Hedging Relationship	Gain or (Loss) Recognized in OCI on Derivative		Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Gain or (Loss) Reclassified from Accumulated OCI into Income
Foreign exchange contracts - forwards	$	(12,524)	Net sales	$	334

Foreign exchange contracts - forwards	1,849		Cost of sales	(448)

Foreign exchange contracts - forwards	1,145		Operating expenses	(266)
Total	$	(9,530)		$	(380)

(In thousands)

Derivatives not Designated as Hedging Instruments

Location of Gain (Loss) Recognized in Income

Amount of Gain (Loss) Recognized in Income

September 30, 2021

September 30, 2020

(Unaudited)

Foreign exchange contracts - forwards

Other expense

(1,679)

(267)

Total

(1,679)

(267)

The following tables present the effect of derivative instruments on our Consolidated Statements of Income for the nine months ended September 30, 2021 and 2020, respectively:


September 30, 2021
(In thousands)
(Unaudited)
Derivatives in Cash Flow Hedging Relationship	Gain or (Loss) Recognized in OCI on Derivative		Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Gain or (Loss) Reclassified from Accumulated OCI into Income
Foreign exchange contracts - forwards	$	23,098	Net sales	$	(5,249)

Foreign exchange contracts - forwards	(2,675)		Cost of sales	(73)

Foreign exchange contracts - forwards	(1,819)		Operating expenses	(70)
Total	$	18,604		$	(5,392)


September 30, 2020
(In thousands)
(Unaudited)
Derivatives in Cash Flow Hedging Relationship	Gain or (Loss) Recognized in OCI on Derivative		Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Gain or (Loss) Reclassified from Accumulated OCI into Income
Foreign exchange contracts - forwards	$	(6,800)	Net sales	$	5,594

Foreign exchange contracts - forwards	(1,898)		Cost of sales	(1,817)

Foreign exchange contracts - forwards	(1,430)		Operating expenses	(1,348)
Total	$	(10,128)		$	2,429


(In thousands)
Derivatives not Designated as Hedging Instruments	Location of Gain (Loss) Recognized in Income	Amount of Gain (Loss) Recognized in Income		Amount of Gain (Loss) Recognized in Income
		September 30, 2021		September 30, 2020
		(Unaudited)		(Unaudited)
Foreign exchange contracts - forwards	Other expense	$	(3,942)	$	(163)
Total		$	(3,942)	$	(163)

Note 6 – Inventories, net

Inventories, net consist of the following:


	September 30, 2021		December 31,
(In thousands)	(Unaudited)		2020

Raw materials	$	131,725	$	99,942
Work-in-process	11,458		11,307
Finished goods	93,550		82,763
Total	$	236,733	$	194,012

Note 7 – Intangible assets, net and goodwill

Intangible assets at September 30, 2021 and December 31, 2020 are as follows:


	September 30, 2021
(In thousands)	(Unaudited)						December 31, 2020
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Capitalized software development costs	$	82,099	$	(68,074)	$	14,025	$	115,251	$	(83,706)	$	31,545
Acquired technology	98,900		(19,017)		79,883		105,486		(17,913)		87,573
Customer relationships	39,747		(15,274)		24,473		40,273		(10,026)		30,247
Patents	35,923		(28,737)		7,186		35,803		(25,578)		10,225
Other	26,885		(15,514)		11,371		27,440		(14,311)		13,129
Total	$	283,554	$	(146,616)	$	136,938	$	324,253	$	(151,534)	$	172,719

Software development costs capitalized for the three months ended September 30, 2021 and 2020 were $0.6 million and $(0.2) million, respectively, and related amortization expense was $5.6 million and $6.9 million, respectively. For the nine months ended September 30, 2021 and 2020, capitalized software development costs were $1.4 million and $3.1 million, respectively, and related amortization expense was $18.9 million and $21.6 million, respectively. Capitalized software development costs for the three months ended September 30, 2021 and 2020 included costs related to stock-based compensation of less than $0.1 million and $0.1 million, respectively. For the nine months ended September 30, 2021 and 2020, capitalized software development costs included costs related to stock-based compensation of $0.2 million and $0.3 million, respectively. The related amounts in the table above are net of fully amortized assets.

Amortization of capitalized software development costs is computed on an individual product basis for those products available for market and is recognized based on the product’s estimated economic life, which generally range from three to six years. Acquired technology, customer relationships and other intangible assets are amortized over their useful lives, which generally range from five to ten years. Patents are amortized using the straight-line method over their estimated period of benefit, which generally range from ten to seventeen years. Total intangible assets amortization expenses were $13.4 million and $14.2 million for the three months ended September 30, 2021 and 2020, respectively, and $43.3 million and $32.9 million for the nine months ended September 30, 2021 and 2020, respectively.

Goodwill

The carrying amount of goodwill as of September 30, 2021, was as follows:



(In thousands)	Amount
Balance as of December 31, 2020	$	467,547
Acquisitions	16,893
Measurement period adjustments	1,973
Foreign currency translation impact	(5,924)
Balance as of September 30, 2021 (unaudited)	$	480,489

The excess purchase price over the fair value of assets acquired is recorded as goodwill. As businesses are acquired, we assign assets acquired (including goodwill) and liabilities assumed to either our existing reporting unit or a newly identified reporting unit as of the date of the acquisition. In the event a disposal group meets the definition of a business, goodwill is allocated to the disposal group based on the relative fair value of the disposal group to the related reporting unit. As we have one operating segment comprised of components with similar economic characteristics, we allocate goodwill to one reporting unit for goodwill impairment testing. Goodwill is tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach based on the market capitalization of the reporting unit. Our annual impairment test is performed in the fourth quarter of each year.

No impairment of goodwill was identified during the nine months ended September 30, 2021 or the twelve months ended December 31, 2020.

Note 8 – Leases

We have operating leases for corporate offices, automobiles, and certain equipment. Our leases have remaining terms of 1 year to 93 years, some of which may include options to extend the leases for up to 9 years, and some of which may include options to terminate the leases within 1 year. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term. Amounts related to finance lease activities and income from leasing activities were not material for the periods presented.

The components of operating lease expense were as follows (unaudited):


	Three Months Ended				Nine Months Ended
(In thousands)	September 30, 2021		September 30, 2020		September 30, 2021		September 30, 2020
Operating Lease Cost (1)	$	5,174	$	4,869	$	15,712	$	15,941
(1) Includes variable and short-term lease costs

Maturities of lease liabilities as of September 30, 2021 were as follows (unaudited):


(In thousands)
Years ending December 31,	Operating Leases
2021 (Excluding the nine months ended September 30, 2021)	$	4,419
2022	12,815
2023	8,638
2024	7,445
2025	4,949
Thereafter	7,067
Total future minimum lease payments	45,333
Less imputed interest	(3,767)
Total lease liabilities	$	41,566

As of September 30, 2021, we have additional operating leases that have not commenced during the nine months ended September 30, 2021, which were not material.

Note 9 – Income taxes

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. We had a valuation allowance of $94 million and $93 million at September 30, 2021 and December 31, 2020, respectively. A majority of the valuation allowance is related to the deferred tax assets of National Instruments Hungary Kft.

We account for uncertainty in income taxes recognized in our financial statements using prescribed recognition thresholds and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on our tax returns. We had $10.9 million and $10.5 million of gross unrecognized tax benefits at September 30, 2021 and December 31, 2020, respectively, all of which would affect our effective income tax rate if recognized. We recorded a gross increase in unrecognized tax benefits of $0.2 million for the three months ended September 30, 2021, as a result of the tax positions taken during prior periods. As of September 30, 2021, it is reasonably possible that we will recognize gross tax benefits in the amount of $1.4 million in the next twelve months due to the closing of open tax years. The nature of the uncertainty is related to deductions taken on returns that have not been examined by the applicable tax authority. Our continuing policy is to recognize interest and penalties related to income tax matters in income tax expense. During the three months ended September 30, 2021, we recognized interest expense related to uncertain tax positions of approximately $40,000. As of September 30, 2021, we had approximately $0.5 million accrued for interest related to uncertain tax positions. The tax years 2014 through 2021 remain open to examination by the major taxing jurisdictions to which we are subject.

Our provision for income taxes reflected an effective tax rate of 16% and (11)% for the three months ended September 30, 2021 and 2020, respectively, and 16% and 24% for the nine months ended September 30, 2021 and 2020, respectively. For the three months ended September 30, 2021, our effective tax rate was lower than the U.S. federal statutory rate of 21% primarily as a result of an enhanced deduction for certain research and development expenses, the U.S. research and development tax credit, foreign taxes lower than the statutory rate and the deduction for foreign-derived intangible income, offset by the U.S. tax on global intangible low-taxed income, state income taxes net of federal benefit, nondeductible officer compensation and excess tax expense from share-based compensation. For the nine months ended September 30, 2021, our effective tax rate was lower than the U.S. federal statutory rate of 21% primarily as a result of an enhanced deduction for certain research and development expenses, the U.S research and development tax credit and the deduction for foreign-derived intangible income, offset by the U.S. tax on global intangible low-taxed income, state income taxes net of federal benefit and nondeductible officer compensation. For the three months ended September 30, 2020, our effective tax rate was lower than the U.S. federal statutory rate of 21% primarily as a result of foreign taxes lower than the statutory rate, the U.S. research and development tax credit, an enhanced deduction for certain research and development expenses and the deduction for foreign-derived intangible income, offset by state income taxes net of federal benefit, nondeductible officer compensation and nondeductible acquisition costs. For the nine months ended September 30, 2020, our effective tax rate was higher than the U.S. federal statutory rate of 21% primarily as a result of state income taxes net of federal benefit, nondeductible officer compensation, foreign taxes greater than the statutory rate, nondeductible acquisition costs and the gain on the sale of our AWR business, offset by the U.S. research and development tax credit, an enhanced deduction for certain research and development expenses, and the deduction for foreign-derived intangible income.

Our earnings from our operations in Hungary are subject to a statutory tax rate of 9%. In addition, our research and development activities in Hungary benefit from a tax law in Hungary that provides for an enhanced deduction for qualified research and development expenses. The tax position of our Hungarian operations resulted in income tax benefits of $1.9 million and $2.2 million for the three and nine months ended September 30, 2021, respectively, and income tax expense of $0.1 million and $0.3 million for the three and nine months ended September 30, 2020, respectively.

Earnings from our operations in Malaysia are free of tax under a tax holiday effective January 1, 2013. This tax holiday expires in 2037. If we fail to satisfy the conditions of the tax holiday, this tax benefit may be terminated early. The income tax benefits of the tax holiday for the three and nine months ended September 30, 2021 were approximately $0.6 million and $0.9 million, respectively. The income tax benefits of the tax holiday for the three and nine months ended September 30, 2020 were approximately $0.2 million and $0.4 million, respectively. The impact of the tax holiday on a per share basis for each of the three and nine months ended September 30, 2021 and September 30, 2020 was approximately $0.01 per share.

No other taxing jurisdictions had a significant impact on our effective tax rate. We have not entered into any advanced pricing or other agreements with the Internal Revenue Service ("IRS") with regard to any foreign jurisdictions.

Note 10 – Comprehensive income

Our OCI is comprised of net income, foreign currency translation adjustments, and unrealized gains and losses on forward contracts and securities classified as available-for-sale. The accumulated OCI, net of tax, for the nine months ended September 30, 2021 and 2020, consisted of the following:


	September 30, 2021
	(Unaudited)
(In thousands)	Currency translation adjustment		Investments		Derivative instruments		Accumulated other comprehensive income/(loss)
Balance as of December 31, 2020	$	(10,066)	$	(426)	(10,334)		$	(20,826)
Current-period other comprehensive (loss) income	(10,585)		(162)		13,213		2,466
Reclassified from accumulated OCI into income	—		—		5,392		5,392
Income (benefit) tax expense	—		(4)		4,212		4,208
Balance as of September 30, 2021	$	(20,651)	$	(584)	$	4,059	$	(17,176)


	September 30, 2020
	(Unaudited)
(In thousands)	Currency translation adjustment		Investments		Derivative instruments		Accumulated other comprehensive income/(loss)
Balance as of December 31, 2019	$	(25,831)	$	(85)	4,846		$	(21,070)
Current-period other comprehensive income (loss)	6,507		(317)		(7,699)		(1,509)
Reclassified from accumulated OCI into income	—		—		(2,429)		(2,429)
Income tax benefit	—		(45)		(2,223)		(2,268)
Balance as of September 30, 2020	$	(19,324)	$	(357)	$	(3,059)	$	(22,740)

Note 11 – Authorized shares of common and preferred stock and stock-based compensation plans

Authorized shares of common and preferred stock

The total number of shares which we are authorized to issue is 365,000,000 shares, consisting of (i) 5,000,000 shares of preferred stock, par value $0.01 per share, and (ii) 360,000,000 shares of common stock, par value $0.01 per share.

Stock-Based Compensation Plan

Our stockholders approved our 2005 Incentive Plan (the “2005 Plan”) on May 10, 2005. At the time of approval, 4,050,000 shares of our common stock were reserved for issuance under the 2005 Plan, as well as the number of shares which had been reserved but not issued under our 1994 Incentive Stock Options Plan (the “1994 Plan”) which terminated in May 2005, and any shares that returned to the 1994 Plan as a result of termination of options or repurchase of shares issued under such plan. The 2005 Plan provided for the granting of incentive awards in the form of restricted stock and RSUs to directors, executive officers and employees of the Company and its subsidiaries. Awards vest over a three, five or ten-year period, beginning on the date of grant. Vesting of ten-year awards may accelerate based on our previous year’s earnings and growth but ten-year awards cannot accelerate to vest over a period of less than five years. The 2005 Plan terminated on May 11, 2010, except with respect to outstanding awards previously granted thereunder. There were 3,362,304 shares of common stock that were reserved but not issued under the 2005 Plan as of May 11, 2010.

Our stockholders approved our 2010 Incentive Plan (the “2010 Plan”) on May 11, 2010. At the time of approval, 3,000,000 shares of our common stock were reserved for issuance under the 2010 Plan, as well as the 3,362,304 shares of common stock that were reserved but not issued under the 1994 Plan and the 2005 Plan as of May 11, 2010, and any shares that are returned to the 1994 Plan and the 2005 Plan as a result of the forfeiture or termination of options or RSUs or repurchase of shares issued under those plans. The 2010 Plan provided for the granting of incentive awards in the form of restricted stock and RSUs to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Awards vest over a three, five or ten-year period, beginning on the date of grant. Vesting of ten-year awards may accelerate based on our previous year’s earnings and growth but ten-year awards cannot accelerate to vest over a period of less than five years. The 2010 Plan terminated on May 12, 2015, except with respect to the outstanding awards previously granted thereunder. There were 2,518,416 shares of common stock that were reserved but not issued under the 2010 Plan as of May 12, 2015.

Our stockholders approved our 2015 Equity Incentive Plan (the “2015 Plan”) on May 12, 2015. At the time of approval, 3,000,000 shares of our common stock were reserved for issuance under the 2015 Plan, as well as the 2,518,416 shares of common stock that were reserved but not issued under the 2010 Plan as of May 12, 2015, and any shares that were returned to the 1994 Plan, 2005 Plan, and the 2010 Plan as a result of the forfeiture or termination of options or RSUs or repurchase of shares issued under those plans. The 2015 Plan provides for the granting of incentive awards in the form of restricted stock and RSUs to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company and such awards may be subject to performance-based vesting conditions. Awards generally vest over a three, four, five or ten-year period, beginning on the date of grant. Vesting of ten-year awards may accelerate based on our previous year’s earnings and growth but ten-year awards cannot accelerate to vest over a period of less than five years. The 2015 Plan terminated on May 5, 2020, except with respect to the outstanding awards previously granted thereunder. There were 567,142 shares of common stock that were reserved but not issued under the 2015 Plan as of May 5, 2020.

Our stockholders approved our 2020 Equity Incentive Plan (the “2020 Plan”) on May 5, 2020. At the time of approval, 4,500,000 shares of our common stock were reserved for issuance under the 2020 Plan, as well as the 567,142 shares of common stock that were reserved but not issued under the 2015 Plan as of May 5, 2020, and any shares that were returned to the 1994 Plan, 2005 Plan, 2010 Plan, and 2015 Plan as a result of the forfeiture or termination of options or RSUs or repurchase of shares issued under those plans. The 2020 Plan provides for the granting of incentive awards in the form of restricted stock and RSUs to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Awards generally vest over a one, two, three or four-year period, beginning on the date of the grant and awards may be subject to performance-based vesting conditions. There were 3,270,415 shares available for grant under the 2020 Plan at September 30, 2021.

Performance-based stock units

During the nine months ended September 30, 2021 and 2020, we granted 130,006 and 144,647 performance-based restricted stock units (“PRSUs”), respectively, to executive officers pursuant to the 2020 Plan and 2015 Plan. The PRSUs may be earned based on our total shareholder return ("TSR") compared to the TSR of the Russell 2000 Index (the “Index”) over a three-year performance period. For the PRSUs granted during the nine months ended September 30, 2021, the three-year performance period commenced on January 1, 2021 and will end on December 31, 2023, and for the PRSUs granted during the nine months ended September 30, 2020, the three year performance commenced on January 1, 2020 and will end on December 31, 2022, using the average daily closing price over a 30-day lookback in each case. The number of awards earned could range from zero to two times the target number of shares granted.

The fair values of PRSUs are estimated using a Monte Carlo simulation. The determination of fair value of the PRSUs is based on our stock price and a number of assumptions including the expected volatility, expected dividend yield and the risk-free interest rate. The expected volatility at the date of grant was based on the historical volatilities of our stock and the companies included in the Index over the performance period. The Monte Carlo model is based on random projections of stock-price paths and must be repeated numerous times to achieve a probabilistic assessment. The key assumptions used in valuing these market-based awards are as follows:


	Nine Months Ended
	(unaudited)
	September 30, 2021	September 30, 2020
Number of simulations	100,000	100,000
Expected volatility	40.60%	27.41%
Expected life in years	2.95 years	2.92 years
Risk-free interest rate	0.21%	1.38%
Dividend yield	2.66%	2.32%

The weighted average grant date fair value of the market-based awards, as determined by the Monte Carlo valuation model, was $66.97 per share and $61.00 per share in 2021 and 2020, respectively.

Employee stock purchase plan

Our employee stock purchase plan (“ESPP”) permits substantially all domestic employees and employees of designated subsidiaries to acquire our common stock at a purchase price of 85% of the lower of the market price at the beginning or the end of the purchase period. The plan has quarterly purchase periods generally beginning on February 1, May 1, August 1 and November 1 of each year. Employees may designate up to 15% of their compensation for the purchase of common stock under the ESPP. On May 14, 2019, our stockholders approved an additional 3,000,000 shares for issuance under our ESPP. At September 30, 2021, we had 2,257,649 shares of common stock reserved for future issuance under the ESPP. We issued 801,543 shares under this plan in the nine months ended September 30, 2021 and the weighted average purchase price was $31.74 per share. During the nine months ended September 30, 2021, we did not make any changes in accounting principles or methods of estimates with respect to our ESPP.

Authorized Preferred Stock and Preferred Stock Purchase Rights Plan

We have 5,000,000 authorized shares of preferred stock. There were no shares of preferred stock issued and outstanding at September 30, 2021.

Stock repurchases and retirements

On April 21, 2010, our Board of Directors authorized a program to repurchase of shares of our common stock from time to time, depending on market conditions and other factors (the "Program"). The Board of Directors has amended the Program several times over the years to increase the number of shares that may be purchased under the Program. Most recently, on October 23, 2019, our Board amended the Program to increase the number of shares that may be repurchased by 3,000,000 shares. At September 30, 2021, there were 1,010,877 shares remaining available for repurchase under the Program. During the three and nine months ended September 30, 2021, we repurchased 599,066 shares of our common stock at a weighted average price per share of $41.73. During the three months ended September 30, 2020, we repurchased 446,502 shares of our common stock at a weighted average price per share of $34.86 and during the nine months ended September 30, 2020, we repurchased 1,114,701 shares of our common stock at a weighted average price per share of $35.21. The Program does not have an expiration date.

Note 12 – Segment and geographic information

We operate as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is our chief executive officer, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker evaluates our financial information and resources and assesses the performance of these resources on a consolidated basis. Since we operate as one operating segment, all required financial segment information can be found in the condensed consolidated financial statements and the notes thereto.

We sell our products in three geographic regions which consist of Americas, EMEA and APAC. Our sales to these regions share similar economic characteristics including the nature of products and services we sell, the type and class of customers, and the methods used to distribute our products and services. Revenue from the sale of our products, which are similar in nature, and software maintenance is reflected as total net sales in our Consolidated Statements of Income. (See Note 2 - Revenue of Notes to Consolidated Financial Statements for total net sales by the major geographic areas in which we operate).

The following table presents summarized information for net sales by country. Revenues from external customers are generally attributed to countries based upon the customer's location. Net sales attributable to each individual foreign country outside the U.S. and China were not material.


(in millions)	United States		China(1)		Rest of the World		Total
Net sales:
Three months ended September 30, 2021	$	141	$	59	$	167	$	367
Three months ended September 30, 2020	$	121	$	52	$	135	$	308

Nine months ended September 30, 2021	$	388	$	172	$	489	$	1,049
Nine months ended September 30, 2020	$	355	$	139	$	425	$	919
(1): Includes Mainland China and the Hong Kong Special Administrative Region

The following table presents summarized information for long-lived assets by country. Long-lived assets attributable to each individual country outside the U.S., Hungary and Malaysia were not material. Long-lived assets consist of property, plant, and equipment, operating lease right-of-use assets and other long-term assets excluding intangible assets.


(in millions)	United States		Hungary		Malaysia		Rest of the World		Total
Long-lived Assets:
September 30, 2021	$	127	$	51	$	75	$	56	$	309
December 31, 2020	$	127	$	52	$	75	$	68	$	322

Note 13 – Debt

On June 18, 2021, we entered into a Second Amended and Restated Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as the administrative agent, swingline lender and issuing lender (the “Administrative Agent”), Wells Fargo Securities, LLC, as sole lead arranger and bookrunner, and the lenders party thereto. The Credit Agreement amended and restated and refinanced our prior Amended and Restated Credit Agreement, dated as of June 12, 2020, by and among us, the lenders from time-to-time party thereto and Administrative Agent, as amended on October 30, 2020.

The Credit Agreement provides for a secured revolving loan facility in an aggregate principal amount of up to $500 million at any time outstanding, with a sublimit of $25 million for the issuance of letters of credit. Subject to the terms and conditions of the Credit Agreement, including obtaining commitments from existing lenders or new lenders, we may request term loans or additional revolving commitments. Pursuant the Credit Agreement, the revolving line of credit terminates, and all revolving loans under the Credit Agreement will be due and payable, on June 18, 2026.

The revolving loans accrue interest, at our option, at a base rate equal to the highest of (a) the prime rate, (b) the federal funds rate plus 0.50%, and (c) a LIBOR loan interest rate of LIBOR for an interest period of one month plus 1.00%, plus a margin of 0.25% to 0.75%, or LIBOR plus a margin of 1.25% to 1.75%, with the margin being determined based upon our consolidated total net leverage ratio. The Credit Agreement contains financial covenants requiring us to maintain a maximum

total net leverage ratio of less than or equal to 3.50 to 1.00, which increases to 4.00 to 1.00 for a specified period following material acquisitions, and a minimum interest coverage ratio of greater than or equal to 3.00 to 1.00, in each case determined in accordance with the Credit Agreement. The Credit Agreement provides for a commitment fee of 0.150% to 0.250% per annum, determined based upon our consolidated total net leverage ratio, on the average daily unused amount of the revolving committed amount, payable quarterly in arrears.

Under the circumstances described in the Credit Agreement, certain of our wholly-owned domestic subsidiaries (the "Subsidiary Guarantors") are required to enter into a guaranty agreement ("Guaranty") in favor of the Administrative Agent guarantying the obligations of the Company under the Credit Agreement, among other things. There is no Subsidiary Guarantor, and no Guaranty has been executed in connection with the Credit Agreement at this time. In connection with the Credit Agreement, we, our Subsidiary Guarantors from time-to-time party thereto and the Administrative Agent have entered (or will enter in the case of the future Subsidiary Guarantors) into an Amended and Restated Collateral Agreement pursuant to which we and each of our Subsidiary Guarantor from time-to-time have granted (or will grant) a lien on substantially all of their assets to secure their obligations under the Credit Agreement and the Guaranty.

The Credit Agreement contains customary affirmative and negative covenants. The affirmative covenants include, among other things, delivery of financial statements, compliance certificates and notices, payment of taxes and other obligations, maintenance of existence, maintenance of properties and insurance, maintenance of books and records, and compliance with applicable laws and regulations. The negative covenants include, among other things, limitations on indebtedness, liens, mergers, consolidations, acquisitions and sales of assets, investments, changes in the nature of the business, affiliate transactions and certain restricted payments. The Credit Agreement contains customary events of default including, among other things, payment defaults, breaches of covenants or representations and warranties, cross-defaults with certain other indebtedness, bankruptcy and insolvency events, judgment defaults and change in control events, subject to grace periods in certain instances. Upon an event of default, the Administrative Agent and the lenders may declare all or a portion of the outstanding obligations payable by us to be immediately due and payable and exercise other rights and remedies provided for under the Credit Agreement. Under certain circumstances, a default interest rate will apply on all obligations during the existence of an event of default under the Credit Agreement at a per annum rate of interest equal to 2.00% above the otherwise applicable interest rate.

Proceeds of revolving loans of the Credit Agreement may be used for working capital and other general corporate purposes. We may prepay the loans under the Credit Agreement in whole or in part at any time without premium or penalty.

The following table presents the amounts outstanding related to our borrowing arrangements discussed above as of September 30, 2021 (unaudited) and December 31, 2020, respectively (in thousands):


	September 30,		December 31,
(in thousands)	2021		2020
Secured
2020 Term loan (effective interest rate of 1.7%)	$	—	$	98,750
2021 Revolving line of credit (effective interest rate of 1.3%)	100,000		—

Total Debt	100,000		98,750
Less: Unamortized debt issuance costs	—		(1,714)
Less: Current portion of total debt	—		(5,000)
Total Debt, non-current	$	100,000	$	92,036

As of September 30, 2021, debt issuance costs of approximately $2.6 million attributable to the revolving line of credit are presented within "Other long-term assets" in our Consolidated Balance Sheet. These amounts are amortized to interest expense ratably over the life of the revolving line of credit.

Please refer to Note 18 - Subsequent Events of Notes to Consolidated Financial Statements for additional information on additional borrowings under our Credit Agreement.

Note 14 – Commitments and contingencies

We offer a one-year limited warranty on most hardware products which is included in the terms of sale of such products. We also offer optional extended warranties on our hardware products for which the related revenue is recognized ratably over the warranty period. Provision is made for estimated future warranty costs at the time of the sale for the estimated costs that may be incurred under the standard warranty. Our estimate is based on historical experience and product sales during the period. The warranty reserve for the nine months ended September 30, 2021 and 2020 was as follows:


	Nine Months Ended September 30,
(In thousands)	(Unaudited)
	2021		2020
Balance at the beginning of the period	$	2,872	$	2,561
Accruals for warranties issued during the period	2,037		1,824
Accruals related to pre-existing warranties	(636)		405
Settlements made (in cash or in kind) during the period	(1,291)		(2,088)
Balance at the end of the period	$	2,982	$	2,702

As of September 30, 2021, we had certain off-balance sheet commitments that require the future purchase of goods or services ("unconditional purchase obligations"). Our unconditional purchase obligations primarily consist of payments to various suppliers for customized inventory and inventory components. As of September 30, 2021, our total future payments under noncancellable unconditional purchase obligations having a remaining term in excess of one year were approximately $3.2 million.

Note 15 – Restructuring

On October 29, 2020, we announced a workforce reduction plan (the “Plan”) intended to accelerate our growth strategy and further optimize our operations and cost structure. The majority of charges related to this Plan were recognized during the three months ended December 31, 2020. We implemented a majority of the actions under this Plan as of September 30, 2021.

A summary of the charges in our consolidated statement of operations resulting from our restructuring activities is shown below:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Cost of sales	$	(7)	$	(13)	$	(50)	$	7
Research and development	65		38		444		4,716
Sales and marketing	(223)		512		3,924		8,055
General and administrative	54		121		2,159		683
Total restructuring and other related costs	$	(111)	$	658	$	6,477	$	13,461

A summary of balance sheet activity related to our restructuring activity is shown below:


(in thousands)	Restructuring Liability
Balance as of December 31, 2020	$	28,993
Income statement expense	6,477
Cash payments	(30,389)
Balance as of September 30, 2021	$	5,081

The restructuring liability of $5.1 million at September 30, 2021 related primarily to severance payments associated with the restructuring activity is recorded in the “accrued compensation” line item of our consolidated balance sheet.

Note 16 – Litigation

We are not currently a party to any material litigation. However, in the ordinary course of our business, we have in the past, are currently and may likely become involved in various legal proceedings, claims, and regulatory, tax or government inquiries and investigations, and could incur uninsured liability in any one or more of them. We also periodically receive notifications from various third parties related to alleged infringement of patents or intellectual property rights, commercial disputes or other matters. No assurances can be given with respect to the extent or outcome of any investigation, litigation or dispute.

Note 17 – Acquisitions

Acquisition of OptimalPlus

On July 2, 2020, we completed the acquisition of OptimalPlus Ltd. (“OptimalPlus”), a global leader in data analytics software for the semiconductor, automotive and electronics industries that is based in Israel. As a result of acquiring 100% of the outstanding share capital of OptimalPlus, OptimalPlus became our wholly-owned subsidiary. This transaction was accounted for as a business combination using the acquisition method of accounting. All of the acquired assets and liabilities of OptimalPlus have been recorded at their respective fair values as of the acquisition date. Transaction costs have been expensed as incurred.

The acquisition was funded primarily by cash on hand in addition to $70 million drawn under our prior term loan facility on June 30, 2020. See Note 13 – Debt of Notes to Consolidated Financial Statements for further information on our outstanding borrowings. During the twelve months ended December 31, 2020, we expensed $7 million of transaction costs in connection with the acquisition of OptimalPlus, which are included in selling, general and administrative expenses.

At the acquisition date, total consideration transferred was approximately $353 million, inclusive of $18 million in cash acquired. Additionally, unvested in-the-money share options of certain OptimalPlus employees were exchanged into the right to receive deferred cash consideration in accordance with the terms of the share purchase agreement. Approximately $12 million of deferred cash consideration was allocated to post-combination expense and is not included in the total consideration transferred. The deferred cash consideration is subject to the original vesting schedule of the corresponding unvested options that were replaced and the amounts will be recognized as compensation expense over the remaining service period.

The excess of the purchase price over the net assets acquired was recorded as goodwill. Goodwill generated from the acquisition is primarily attributable to expected growth in the scope of and market opportunities for our software-defined automated test and measurement platform. As a result of the structure of the transaction, the balance of goodwill is deductible in the U.S. over 15 years for income tax purposes.

Fair value of net assets acquired and liabilities assumed

The information below represents the purchase price allocation of OptimalPlus:


(in thousands)	July 2, 2020
Consideration Transferred	$	352,642

Cash	17,661
Intangible assets	129,000
Goodwill	205,038
Contract assets	15,454
Deferred revenue	(7,341)
Accounts receivable	4,927
Other assets and liabilities	(4,516)
Deferred tax liabilities	(7,581)
Net assets acquired	$	352,642

We finalized the purchase price allocation for our acquisition of OptimalPlus during the second quarter of 2021. Since the preliminary estimates reported in the third quarter of 2020, we updated certain amounts related to current and deferred income taxes, reflected in the final purchase price allocation, as summarized in the fair values of assets acquired and liabilities assumed in the table above. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date.

Acquired intangible assets will be amortized over their estimated useful lives on a straight-line basis. The following table summarizes the purchase price allocation, and the average remaining useful lives, for identifiable intangible assets acquired:


(dollars in thousands)	Estimated Fair Value		Estimated Useful Lives (in years)
Customer relationships	$	30,100	5

Developed technology	82,400		6
In-process research and development (IPR&D)	10,400		6

Other intangibles	6,100		3-5
Total	$	129,000

Developed technology and IPR&D relate to software platforms for data analytics in the semiconductor, automotive, and electronic industries that combine machine-learning with a global data infrastructure to provide real-time product analytics and extract insights from data across the entire supply chain. We valued the developed technology and IPR&D using the multi-period excess earnings method under the income approach. This method reflects the present value of the projected cash flows that are expected to be generated by the technology less charges representing the contribution of other assets to those cash flows. The economic useful life was determined based on the technology cycle related to each technology, as well as the cash flows over the forecast period. IPR&D was initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When a project underlying reported IPR&D is completed, the corresponding amount of IPR&D is amortized over the asset’s estimated useful life.

Customer relationships represent the fair value of future projected revenue that will be derived from sales of products to existing customers. Customer relationships were valued using the with-and-without-method under the income approach. In the with-and-without method, the fair value was measured by the difference between the present values of the cash flows with and without the existing customers in place over the period of time necessary to reacquire the customers. The economic useful life was determined by evaluating many factors, including the useful life of other intangible assets, the length of time remaining on the acquired contracts and the historical customer turnover rates.

Unaudited Pro Forma Information

The results of OptimalPlus have been included in our consolidated statements of income for the period subsequent to the acquisition date. The following unaudited pro forma financial information presents combined results of operations for the periods presented, as if the OptimalPlus acquisition had occurred on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition. These pro forma adjustments include additional amortization expense for the identifiable intangible assets, a reduction in revenue related to deferred revenue purchase accounting adjustments, an increase in interest expense related to the term loan entered into in connection with the acquisition, and adjustments to compensation expense for the replacement of unvested share options discussed above, net of tax effects. For the pro forma presentation, given the assumed acquisition date of January 1, 2019, transaction and integration costs that were incurred at or subsequent to the actual acquisition date have been included in the calculation of pro forma net income for the three and nine months ended September 30, 2020, whereas transaction and integration costs that were incurred prior to the acquisition date have been excluded from the calculation of pro forma net income. The unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what actual results of operations would have been if the acquisition had occurred as the beginning of the period presented, nor are they indicative of future results of operations. The unaudited pro forma results do not include the impact of synergies, nor any potential impacts on current or future market conditions which could alter the unaudited pro forma results.


	Three Months Ended September 30,		Nine Months Ended September 30,
	2020
(in thousands)
Net sales	$	309,142	$	929,381
Net income	$	4,907	$	123,676

Other Acquisitions

During the second quarter of 2021, we also completed the acquisition of a software company that specializes in signal processing and hi-fi simulation software for validation of autonomous vehicles and advanced driver assistance systems (ADAS), for approximately $20 million in total cash consideration, subject to certain post-closing adjustments. This transaction was accounted for as a business combination using the acquisition method of accounting. All of the acquired assets and liabilities of the software company have been recorded at their respective fair values as of the acquisition date. We recognized approximately $17 million of goodwill and $4 million of other intangible assets as part of our preliminary purchase price allocation. Transaction costs have been expensed as incurred and were not material to the periods presented.

The preliminary purchase price allocation related to the acquisition was not finalized as of September 30, 2021, and is based upon a preliminary valuation which is subject to change as we obtain additional information with respect to certain intangible assets and income taxes. Pro-forma results of operations have not been presented because the effects of the acquired operations were not material.

Note 18 – Subsequent events

Dividends

On October 19, 2021, our Board of Directors declared a quarterly cash dividend of $0.27 per common share, payable on November 29, 2021, to stockholders of record on November 8, 2021.

Acquisitions

On October 19, 2021, we completed the acquisition of NH Research (NHR), a manufacturer of test and measurement solutions for high power applications including electric vehicles and batteries. This transaction is being accounted for as a business combination. All of the acquired assets and liabilities of the acquired business will be recorded at their respective fair values as of the acquisition date. Transaction costs will be expensed as incurred. At the acquisition date, total consideration transferred was approximately $200 million, inclusive of $3 million in cash acquired. The acquisition was funded by $200 million drawn under our existing credit facility in October 2021. See Note 13 - Debt of Notes to Consolidated Financial Statements for further information on our outstanding borrowings.

We have excluded certain disclosures required under ASC Topic 805. Disclosure of certain information has been deemed impracticable primarily due to the short period of time we have had to obtain the necessary information from the acquired company, which is not a public company. This short timeframe prohibits us from fully applying various valuation methodologies and preparing the information for this Quarterly Report on Form 10-Q for the third quarter of 2021. Such information, as required under Topic 805, will be included in our Annual Report on Form 10-K for the year ended 2021, and finalized within the one-year measurement period.

Restructuring

On October 26, 2021, we initiated a restructuring plan (the “2021 Plan”) that will result in the site closure of our facilities in Aachen, Germany. This targeted restructuring effort is intended to accelerate our growth strategy and further optimize our operations and cost structure. In connection with the 2021 Plan, we currently estimate that we will incur pre-tax charges of approximately $8 million to $9 million, consisting primarily of severance payments and other employee-related costs. We expect that the majority of these charges will be recognized during the fourth quarter of 2021.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

National Instruments Corporation and its subsidiaries (referred to as the “Company,” “we,” “us,” “our,” “National Instruments” or “NI”) has made forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Any statements contained herein regarding our future financial performance, operations, plans, investments, expected effects of investments, or other matters (including, without limitation, statements to the effect that we “believe,” “expect,” “plan,” “intend to,” “may,” “will,” “project,” “anticipate,” “continue,” “strive to,” “endeavor to,” “seek to,” “are committed to,” "remaining committed to," “are encouraged by,” "remain cautious," "remain optimistic," “estimate”, "focus on"; statements of “goals,”“commitments,” "strategy" or “visions”; or other variations thereof or comparable terminology or the negative thereof) should be considered forward-looking statements. All forward-looking statements are based on current expectations and projections of future events. We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not guarantees of performance and actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including those set forth under the heading “Risk Factors” below and in "Part 1, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the "Form 10-K"). Actual results could differ materially from those stated or implied by our forward-looking statements, due to risks and uncertainties associated with our business or under different assumptions or conditions. You should not place undue reliance on any of these forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The following discussion should be read in conjunction with the Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") and the condensed consolidated financial statements and accompanying notes included in Part 1, Item 1 of this Form 10-Q.

Overview and Current Business Outlook

For more than 40 years, we have enabled engineers and scientists around the world to accelerate productivity, innovation and discovery. Our software-centric platform provides an advanced approach through integration of software and modular hardware to create automated test and automated measurement systems. We believe our long-term track record of innovation and our differentiated platform help support the success of our customers, employees, suppliers, community and stockholders. We have been profitable in every year since 1990. We sell to a large number of customers in a wide variety of industries.

The key strategies that we focus on in running our business are the following:

•Expanding our available market opportunity

We strive to increase our available market by identifying new opportunities in existing customers, attracting and serving new customers, and expanding our business to market adjacencies. Our large network of existing customers provides a broad base from which to expand.

•Maintaining a high level of customer satisfaction

To maintain a high level of customer satisfaction we strive to offer innovative, modular and integrated products through a global sales and support network. We strive to maintain a high degree of backward compatibility across different platforms to preserve the customer’s investment in our products. In this time of intense global competition, we believe it is crucial that we continue to offer products with high quality and reliability, and that our products provide cost-effective solutions for our customers.

•Leveraging external and internal technology

Our product strategy is to provide superior products by leveraging generally available technology, supporting open architectures on multiple platforms and by leveraging our core technologies across multiple products.

We sell into test and measurement and industrial/embedded applications in a broad range of industries and are subject to the economic and industry forces that drive those markets. Examples of these types of customers include semiconductor, transportation, and aerospace, defense and government ("ADG").

•Leveraging a worldwide sales, distribution and manufacturing network

We distribute and sell our software and hardware products primarily through a direct sales organization. We also use independent distributors, original equipment manufacturers, value added resellers, system integrators, and consultants to market and sell our products. We have sales offices in the U.S. and sales offices and distributors in key international markets. Sales outside of the Americas accounted for approximately 59% and 59% of our net sales during the three months ended September 30, 2021 and 2020, respectively, and approximately 61% and 59% of our net sales during the nine months ended September 30, 2021 and 2020, respectively. The vast majority of our foreign sales are denominated in the customers’ local currency, which exposes us to the effects of changes in foreign currency exchange rates. We expect that a significant portion of our total revenues will continue to be derived from international sales. (See Note 2 - Revenue and Note 12 - Segment and geographic information of Notes to Consolidated Financial Statements for details concerning the geographic breakdown of our net sales and long-lived assets, respectively).

We manufacture substantially all of our product volume at our facilities in Debrecen, Hungary and Penang, Malaysia.

•Delivering high quality, reliable products

We believe that our long-term growth and success depend on delivering high quality software and hardware products on a timely basis. Accordingly, we focus significant efforts on research and development. We focus our research and development efforts on enhancing existing products and developing new products that incorporate appropriate features and functionality to be competitive with respect to technology, price and performance. Our success also depends on our ability to obtain and maintain patents and other proprietary rights related to technologies used in our products. We have engaged in litigation when necessary, and will likely engage in future litigation to protect our intellectual property rights.

Our operating results fluctuate from period to period due to changes in global economic conditions and a number of other factors such as the impact of the COVID-19 pandemic. As a result, we believe our historical results of operations should not be relied upon as indications of future performance. There can be no assurance that our net sales will grow, or not decline, or that we will remain profitable in future periods.

Current Business Outlook

During the third quarter of 2021, we continued to see strong demand from our customers across the geographic regions and end markets that we serve, with the value of total orders increasing by approximately 30% compared to the same period in 2020. Although the strength and duration of the recent trends will vary by region and end market, we remain optimistic about opportunities for additional revenue growth during the remainder of 2021 and beyond. We expect our customers will continue to make investments in emerging technologies related to 5G/mmWave, vehicle electrification, and advanced driver assistance systems (ADAS). We also anticipate that recent additions and enhancements to our software offerings will differentiate our products and fuel demand across our various end markets.

We continue to experience shortages of certain components in our supply chain due to global capacity constraints that were amplified by the COVID-19 pandemic and increasing global demand. Historically, our backlog levels have remained fairly consistent at the end of each quarter, representing approximately a week of quarterly sales activity, and the majority of these orders are fulfilled quickly within the following quarter. However, due to the shortage of certain components from our suppliers and the increase in demand from our customers, our backlog at the end of the third quarter was more than six times the historical average, representing more than one month of quarterly sales activity. Longer lead times to fulfill orders for certain offerings have continued to shift the timing of revenue recognition into future periods and increased our costs to obtain a consistent supply of certain components. Consequently, while we expect some temporary headwinds related to the supply chain constraints to continue while global supply chains adjust to the significant increases in demand, we are optimistic about our ability to maintain competitive lead times while continuing to maintain higher backlog levels as part of our strategic focus on system offerings through the remainder of 2021 and beyond.

We remain committed to maintaining our critical investments and capacity to run our business while continuing to innovate. Furthermore, we continue to focus on scale and efficiency in serving our broad-based customers. Our focus to streamline the process of doing business with NI means both reducing our costs and improving the experience of the large number of smaller accounts we serve. This commitment and focus include plans to invest in ni.com for a better digital experience and continue to significantly expand the usage of our distributor channel during 2021 and beyond. We believe these actions will allow our direct sales force to support proactive engagements with accounts where we can deliver enterprise-level value.

During the three months ended September 30, 2021, sales to our distributors represented approximately 12% of our total sales, compared to 2% in the same period of 2020 and during the nine months ended September 30, 2021, sales to our distributors represented approximately 8% of our total net sales, compared to 2% in the same period of 2020. As of September 30, 2021, our distributors were not carrying significant amounts of our products in inventory and were not eligible for any variable adjustments related to their previous purchases. As of September 30, 2021 no single distributor accounted for more than 2% of our total net sales.

As part of our efforts to streamline the process of doing business with NI, we have also increased our focus on customer account tiers when assessing trends in our order growth. Specifically, we have grouped our customers into tiers based on their historical spending patterns and potential for future order growth. Our "Focus" account tiers are comprised of approximately 2,500 accounts we have identified as having a high potential to maintain or expand our business through system-level offerings. The Focus tier currently represents approximately 70% of our total order value. Our "Broad-based" account tier is comprised of the remainder of our customer base of approximately 30,000 accounts. The Broad-based tier currently represents approximately 30% of our total order value. During the three months ended September 30, 2021, orders from our Focus accounts and Broad-based accounts increased by 27% and 37%, respectively, compared to the same period in 2020.

During the nine months ended September 30, 2021, we saw continued volatility in the exchange rates between the U.S. dollar and many of the currency markets where we have exposure. The U.S. dollar index, as tracked by the St. Louis Federal Reserve, was approximately 5% weaker compared to the first nine months of 2020 resulting in a modest year over year benefit to our US dollar equivalent sales. We cannot predict to what degree foreign currency markets will fluctuate in the future. See Results of Operations - Net Sales below for additional discussion on the impact of foreign exchange rates on our net sales and Note 5 - Derivative instruments and hedging activities of Notes to Consolidated Financial Statements for a further description of our derivative instruments and hedging activities.

Acquisitions and divestitures

Refer to Note 1 - Basis of presentation and Note 17 - Acquisitions of Notes to Consolidated Financial Statements for additional information on our acquisitions and divestitures during the periods presented.

Critical Accounting Estimates

In preparing our consolidated financial statements, we make assumptions, judgments and estimates that can have a significant impact on our net sales, operating income and net income, as well as on the value of certain assets and liabilities on our condensed consolidated balance sheets. We base our assumptions, judgments and estimates on historical experience and other factors that we believe to be reasonable under the circumstances. At least quarterly, we evaluate our assumptions, judgments and estimates, and make changes as deemed necessary.

These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. For further information about our critical accounting estimates, see the discussion in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” under the heading “Critical Accounting Estimates” in our Form 10-K. There have been no material changes to our critical accounting policies and estimates since the Form 10-K.

Results of Operations

The following table sets forth, for the periods indicated, the percentage of net sales represented by certain items reflected in our Consolidated Statements of Income:


	Three Months Ended September 30,				Nine Months Ended September 30,
	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Net sales:
Americas	40.6	%	41.2	%	39.1	%	40.7	%
EMEA	25.8		25.5		25.7		26.1
APAC	33.6		33.3		35.2		33.2
Total net sales	100.0		100.0		100.0		100.0
Cost of sales	28.0		29.9		28.3		28.5
Gross profit	72.0		70.1		71.7		71.5
Operating expenses:
Sales and marketing	31.9		35.6		32.9		36.0
Research and development	22.4		23.0		23.2		22.5
General and administrative	8.5		12.1		9.0		10.1

Total operating expenses	62.7		70.8		65.1		68.6
Gain on sale of business/asset	—		—		—		17.4
Operating income	9.3		(0.7)		6.5		20.3
Other expense	(0.5)		(0.6)		(0.9)		(0.3)
Income before income taxes	8.8		(1.3)		5.6		20.0
Provision for income taxes	1.4		0.2		0.9		4.9
Net income	7.4	%	(1.5)	%	4.7	%	15.1	%

Figures may not sum due to rounding.

Results of Operations for the three and nine months ended September 30, 2021 and 2020

Net Sales. The following table sets forth our net sales for the three and nine months ended September 30, 2021 and 2020 along with the changes between the corresponding periods.


	Three Months Ended September 30,						Nine Months Ended September 30,
	(Unaudited)						(Unaudited)
					Change						Change
(In millions)	2021		2020		Dollars	Percentage	2021		2020		Dollars	Percentage

Product sales	$	325.7	$	269.7	56.1	21%	$	927.3	$	809.9	117.4	14%
Software maintenance sales	41.4		38.5		3.0	8%	121.7		108.9		12.8	12%
Total net sales	$	367.2	$	308.1	59.0	19%	$	1,049.0	$	918.8	130.2	14%

Figures may not sum due to rounding.

Net Sales - Summary

Net sales for the three and nine months ended September 30, 2021 were up 19 percent and 14 percent, respectively, compared to the same period in 2020.

•The increase in product sales was primarily attributable to stronger demand for our system-level offerings, particularly in semiconductor and electronics test solutions as well as our transportation-related offerings. Net sales in those end markets increased more than 40 percent for the three months ended September 30, 2021 compared to the same period in 2020. Additionally, we implemented price increases for certain offerings which increased net sales by approximately 5 percent compared to the same periods in 2020.

•The increase in software maintenance sales was primarily related to additional billings from our software-related recurring revenue streams during the trailing twelve months, including annual renewals of software maintenance programs and the software-maintenance component of our subscription licensing offerings, which consist primarily of our enterprise-level licenses for LabVIEW and our product analytics offerings.

Net Sales by Region

The following table sets forth our net sales by geographic region for the three and nine months ended September 30, 2021 and 2020 along with the changes between the corresponding periods and the region’s percentage of total net sales.


	Three Months Ended September 30,						Nine Months Ended September 30,
	(Unaudited)						(Unaudited)
					Change						Change
(In millions)	2021		2020		Dollars	Percentage	2021		2020		Dollars	Percentage

Americas	$148.9		$127.0		21.9	17%	$410.3		$373.8		36.5	10%
Percentage of total net sales	40.6	%	41.2	%			39.1	%	40.7	%

EMEA	$94.9		$78.5		16.3	21%	$269.6		$239.9		29.6	12%
Percentage of total net sales	25.8	%	25.5	%			25.7	%	26.1	%

APAC	$123.4		$102.5		20.9	20%	$369.2		$305.1		64.0	21%
Percentage of total net sales	33.6	%	33.3	%			35.2	%	33.2	%

Figures may not sum due to rounding.

We expect sales outside of the Americas to continue to represent a significant portion of our net sales. We intend to continue to expand our international operations by increasing our presence in existing markets, adding a presence in certain new geographical markets and continuing to increase the use of distributors to sell our products in some countries. Almost all of the sales made by our direct sales offices in the Americas (excluding the U.S.), EMEA, and APAC are denominated in local currencies, and accordingly, the U.S. dollar equivalent of these sales is affected by changes in foreign currency exchange rates. In order to provide a framework for assessing how our underlying business performed excluding the effects of foreign currency fluctuations between periods, we compare the percentage change in our results from period to period using constant currency disclosure. To calculate the change in constant currency, current and comparative prior period results for entities reporting in currencies other than U.S. Dollars are converted into U.S. Dollars at constant exchange rates (i.e., the average rates in effect during the three and nine months ended September 30, 2020).

The following tables present this information, along with the impact of changes in foreign currency exchange rates on sales denominated in local currencies, for the three and nine months ended September 30, 2021.


	Three Months Ended September 30, 2020		Change in Constant Dollars		Impact of changes in foreign currency exchange rates on net sales		Three Months Ended September 30, 2021
(In millions)	GAAP Net Sales		Dollars	Percentage	Dollars	Percentage	GAAP Net Sales

Americas	$	127.0	21.6	17.0%	0.3	0.2%	$	148.9
EMEA	$	78.5	14.9	19.0%	1.4	1.8%	$	94.9
APAC	$	102.5	17.6	17.1%	3.3	3.2%	$	123.4
Total net sales	$	308.1	54.1	17.6%	4.9	1.6%	$	367.2

	Nine months ended September 30, 2020		Change in Constant Dollars		Impact of changes in foreign currency exchange rates on net sales		Nine months ended September 30, 2021
(In millions)	GAAP Net Sales		Dollars	Percentage	Dollars	Percentage	GAAP Net Sales

Americas	$	373.8	35.8	9.6%	0.7	0.2%	$	410.3
EMEA	$	239.9	21.5	9.0%	8.2	3.4%	$	269.6
APAC	$	305.1	53.4	17.5%	10.7	3.5%	$	369.2
Total net sales	$	918.8	110.6	12.0%	19.6	2.2%	$	1,049.0

Figures may not sum due to rounding.

To help protect against changes in U.S. dollar equivalent value caused by fluctuations in foreign currency exchange rates of forecasted foreign currency cash flows resulting from international sales, we have a foreign currency cash flow hedging program. We hedge portions of our forecasted net sales denominated in foreign currencies with average rate forward contracts. During the three months ended September 30, 2021 and 2020, these hedges had the effect of decreasing our net sales by $0.8 million and increasing our net sales by $0.3 million, respectively. During the nine months ended September 30, 2021 and 2020, these hedges had the effect of decreasing our net sales by $5.2 million and increasing our net sales by $5.6 million, respectively. (See Note 5 - Derivative instruments and hedging activities of Notes to Consolidated Financial Statements for further discussion regarding our cash flow hedging program and its related impact on our net sales for 2021 and 2020).

Gross Profit. Our gross profit as a percentage of sales is impacted by many factors including changes in the amount of revenues from our large customers and changes in the foreign currency exchange markets. We continue to focus on cost control and cost reduction measures throughout our manufacturing cycle. The following table sets forth our gross profit and gross profit as a percentage of net sales for the three and nine months ended September 30, 2021 and 2020 along with the percentage changes in gross profit for the corresponding periods.


	Three Months Ended September 30,		Nine Months Ended September 30,
	(Unaudited)		(Unaudited)

(In millions)	2021	2020	2021	2020

Gross Profit	$264.4	$215.9	$751.7	$656.9
% change compared with prior period	22.5%		14.4%
Gross Profit as a percentage of net sales	72.0%	70.1%	71.7%	71.5%

The increases in our gross profit and gross profit as a percentage of net sales were primarily related to the following:


	Three Months Ended		Nine Months Ended
	(Unaudited)		(Unaudited)
September 30, 2020	70.1	%	71.5	%
Impact of amortization of acquired intangible and other purchase accounting adjustments	0.1	%	(0.9)	%
Impact of increases in outbound freight and other logistics costs	(0.2)	%	(0.3)	%
Impact of change in excess and obsolescence reserve	(0.4)	%	(0.3)	%
Impact of changes in sales mix and sales price	1.9	%	1.2	%
Changes in foreign currency exchange rates	0.5	%	0.5	%
September 30, 2021	72.0	%	71.7	%

To help protect against changes in our cost of sales caused by a fluctuation in foreign currency exchange rates of forecasted foreign currency cash flows, we have a foreign currency cash flow hedging program. We hedge portions of our forecasted costs of sales denominated in foreign currencies with average rate forward contracts. During the three months ended September 30, 2021 and 2020, these hedges had the effect of increasing our cost of sales by $0.1 million and increasing our cost of sales by $0.4 million, respectively. During the nine months ended September 30, 2021 and 2020, these hedges had the effect of increasing our cost of sales by $0.1 and $1.8 million, respectively. (See Note 5 - Derivative instruments and hedging activities of Notes to Consolidated Financial Statements for further discussion regarding our cash flow hedging program and its related impact on our cost of sales for 2021 and 2020).

Operating Expenses. The following table sets forth our operating expenses for the three and nine months ended September 30, 2021 and 2020, along with the percentage changes between the corresponding periods and the line item as a percentage of total net sales.


	Three Months Ended September 30,					Nine Months Ended September 30,
	(Unaudited)					(Unaudited)
(In thousands)	2021		2020		Change	2021		2020		Change

Sales and marketing	$	117,065	$	109,774	7%	$	345,048	$	330,939	4%
Percentage of total net sales	32%		36%			33%		36%

Research and development	$	82,165	$	70,802	16%	$	243,685	$	206,648	18%
Percentage of total net sales	22%		23%			23%		22%

General and administrative	$	31,037	$	37,431	(17)%	$	94,672	$	92,980	2%
Percentage of total net sales	8%		12%			9%		10%




Total operating expenses	$	230,267	$	218,007	6%	$	683,405	$	630,567	8%
Percentage of total net sales	63%		71%			65%		69%

Operating Expenses - Three Months Ended September 30, 2021

The year over year increase of $12 million in our operating expenses during the three months ended September 30, 2021 was primarily related to the following:

•$18 million increase in personnel costs, primarily attributable to additional accruals for expected attainment under our variable compensation programs and stock-based compensation expense (due to comparatively higher stock prices on the grant date of unvested awards and a shorter average service period for our awards) partially offset by a reduction in severance-related costs associated with our restructuring activities;

•$2 million increase in external service providers and travel expenses related to strategic initiatives and loosening of restrictions related to the COVID-19 pandemic;

•$2 million increase related to the year over year impact of changes in foreign currency exchange rates; and

•$10 million decrease attributable to lower acquisition-related transaction and integration costs.

Sales and Marketing

The primary drivers of the increase in sales and marketing expenses for the three months ended September 30, 2021 compared to the same period in 2020 were additional costs related to accruals under our variable compensation programs, additional costs related to advertising and stock-based compensation, which were partially offset by lower severance-related charges and salaries due to a reduction in headcount.

Research and Development

The primary drivers of the increase in research and development expenses for the three months ended September 30, 2021 compared to the same period in 2020 were additional personnel costs related to accruals under our variable compensation programs, salaries and stock-based compensation expense.

General and administrative

The primary drivers of the decrease in general and administrative expenses for the three months ended September 30, 2021 compared to the same period in 2020 were decreases in acquisition-related transaction costs, partially offset by additional personnel costs related to accruals under our variable compensation programs and stock-based compensation expense.

Operating Expenses - Nine Months Ended September 30, 2021

The year over year increase of $53 million in our operating expenses during the nine months ended September 30, 2021 was primarily related to the following:

•$25 million increase in non-acquisition personnel costs, primarily attributable to additional accruals for estimated attainment under our variable compensation programs and additional stock-based compensation expense (due to comparatively higher stock prices on the grant date of unvested awards and a shorter average service period for our awards), partially offset by lower severance-related costs

•$16 million increase related to the amortization of acquisition-related intangibles, additional operating costs of our acquired OptimalPlus business, and transaction and integration costs related to a one-time redemption fee associated with recently acquired intellectual property;

•$7 million increase related to the year over year impact of changes in foreign currency exchange rates;

•$3 million increase in advertising and external service providers spending partially offset by lower travel spending related to the COVID-19 pandemic travel restrictions; and

•$2 million increase related to a decrease in software development costs eligible for capitalization.

Sales and Marketing

The primary drivers of the increase in sales and marketing expenses for the nine months ended September 30, 2021 compared to the same period in 2020 were additional costs associated with accruals under our variable compensation programs, marketing and advertising costs, and the amortization of acquired intangibles, which were partially offset by lower severance-related costs and lower salaries related to lower headcount.

Research and Development

The primary drivers of the increase in research and development expenses for the nine months ended September 30, 2021 compared to the same period in 2020 were additional personnel costs associated with accruals under our variable compensation programs, higher salaries, stock-based compensation, as well as an anticipated decrease in software development costs eligible for capitalization, which were partially offset by lower severance-related costs.

General and administrative

The primary drivers of the increase in general and administrative expenses for the nine months ended September 30, 2021 compared to the same period in 2020 were additional personnel costs associated with accruals under our variable compensation programs, stock-based compensation, and severance, as well as a one-time redemption fee associated with recently acquired intellectual property.

Gain on sale of business/assets. As previously disclosed, on January 15, 2020, we completed the sale of our AWR subsidiary and recognized a gain on the sale of $160 million. These amounts are presented as "Gain on sale of business/assets" in our Consolidated Statements of Income.

Operating Income (loss). For the three months ended September 30, 2021 and 2020, operating income was $34 million and $(2) million, respectively. As a percentage of net sales, operating income was 9.3% and (0.7)% for the three months ended September 30, 2021 and 2020, respectively. For the nine months ended September 30, 2021 and 2020, operating income was $68 million and $186 million, respectively. As a percentage of net sales, operating income was 6.5% and 20.3% for the nine months ended September 30, 2021 and 2020, respectively. The increase in operating income in absolute dollars for the three months ended September 30, 2021, compared to the three months ended September 30, 2020, is attributable to the factors discussed in Net Sales, Gross Profit and Operating Expenses above. The decrease in operating income in absolute dollars for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, is primarily attributable to the approximately $160 million gain on sale of our AWR subsidiary in 2020, partially offset by the factors discussed in Net Sales, Gross Profit and Operating Expenses above.

Other (Expense) Income.

• Interest Income. For the three months ended September 30, 2021 and 2020, interest income was $0.1 million and $0.4 million, respectively. For the nine months ended September 30, 2021 and 2020, interest income was $0.3 million and $3.7 million, respectively. During the nine months ended September 30, 2021, the Federal Reserve maintained the federal funds rate target to a range of zero to 0.25%. This will likely continue to have a negative impact on our interest income for the remainder of 2021.

• Interest Expense. For the three months ended September 30, 2021 and 2020, interest expense was approximately $0.7 million and $1.0 million, respectively. For the nine months ended September 30, 2021 and 2020, interest expense was approximately $2.6 million, and $1.1 million, respectively. These interest charges are due to interest on outstanding borrowings, commitment fees and amortization of deferred costs related to our Credit Agreement. During the nine-month period ended September 30, 2021, we amended and restated in its entirety and refinanced our existing Credit Agreement. We recognized approximately $0.6 million of expense related to the portion of debt issuance costs that were allocated to the previous Credit Agreement and accounted for as an extinguishment of debt during the second quarter of 2021. Refer to Note 13 - Debt of Notes to Consolidated Financial Statements for additional information regarding the terms of our Credit Agreement and related borrowings.

•Gain (Loss) From Equity-Method Investments. For the three months ended September 30, 2021, gain from equity-method investments was approximately $0.3 million and for the three months ended September 30, 2020, loss from equity-method investments was approximately $0.6 million. For the nine months ended September 30, 2021 and 2020, loss from equity-methods investment was approximately $5.1 million and $2.6 million, respectively. The increase in the nine months ended September 30, 2021 compared to the same period in 2020 was primarily attributable to an impairment loss of $3.5 million recorded in the three months ended March 31, 2021.

•Net Foreign Exchange Gain/Loss. For the three months ended September 30, 2021 and 2020, net foreign exchange loss was $1.2 million and $0.7 million, respectively. During the nine months ended September 30, 2021 and 2020, net foreign exchange loss was $2.7 million and $2.0 million, respectively. Gains and losses on foreign currency are primarily due to the impact of re-measuring foreign currency transactions into the functional currency of the corresponding entity. The amount of the gain or loss on foreign currency is driven by the volume of foreign currency transactions and the foreign currency exchange rates for the period. We recognize the local currency as the functional currency in virtually all of our international subsidiaries. See “Results of Operations - Net Sales” above for additional discussion on the impact of foreign exchange rates on our net sales of operations for the three and nine months ended September 30, 2021.

Provision for Income Taxes. For the three months ended September 30, 2021 and 2020, our provision for income taxes reflected an effective tax rate of 16% and (11)%, respectively. For the nine months ended September 30, 2021 and 2020, our provision for income taxes reflected an effective tax rate of 16% and 24%, respectively. The factors that caused our effective tax rate to change year over year are detailed in the table below:


	Three Months Ended		Nine Months Ended
	September 30, 2021		September 30, 2021
	(Unaudited)		(Unaudited)
Effective tax rate at September 30, 2020	(11)	%	24	%
Employee share-based compensation and other discrete items	(5)		(5)
Nondeductible acquisition costs	(4)		(4)
State income taxes, net of federal benefit	(2)		(2)
Nondeductible officer compensation	(1)		(1)
Enhanced deduction for certain research and development expenses	(1)		(1)
Change in intercompany prepaid tax asset	(1)		(1)
Transition tax on deferred foreign income	—		(1)
Gain on sale of AWR business	—		5
Research and development tax credit	1		3
Change in unrecognized tax benefits	2		1
Global intangible low-taxed income inclusion	7		3
Foreign-derived intangible income deduction	8		3
Foreign taxes greater than federal statutory rate	23		(8)
Effective tax rate at September 30, 2021	16	%	16	%

Other operational metrics

We believe that the following additional unaudited operational metrics assist investors in assessing our operational performance relative to others in our industry and to our historical results. The following tables provide details with respect to the amount of GAAP charges related to certain items that were recorded in the line items indicated below.


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Stock-based compensation
Cost of sales	$	1,183	$	1,051	$	3,487	$	2,787
Sales and marketing	6,332		5,184		18,949		16,826
Research and development	5,811		4,692		17,704		12,640
General and administrative	5,530		4,293		16,050		10,301
Provision for income taxes	(2,798)		(3,854)		(10,036)		(8,260)
Total	$	16,058	$	11,366	$	46,154	$	34,294


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Amortization of acquisition-related intangibles and fair value adjustments
Net sales	$	421	$	1,299	$	1,971	$	1,299
Cost of sales	$	4,194	$	4,198	$	12,691	$	5,579
Sales and marketing	2,331		2,334		6,859		3,300
Research and development	—		28		—		84
Other expense	529		121		1,476		363
Provision for income taxes	(917)		(1,658)		(2,870)		(1,948)
Total	$	6,558	$	6,322	$	20,127	$	8,677


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Acquisition-related transaction and integration costs, restructuring charges, and other(1)(2)
Cost of sales	$	(7)	$	(13)	$	(50)	$	7
Sales and marketing	584		1,158		6,071		8,771
Research and development	386		374		1,422		5,190
General and administrative	850		10,210		7,388		12,595


Gain on sale of business/assets	—		—		—		(159,753)
Other expense	316		270		4,322		397
Provision for income taxes	(238)		(712)		(3,701)		33,965
Total	$	1,891	$	11,287	$	15,452	$	(98,828)
(1): During the first quarter of 2020, we recognized a gain of approximately $160 million related to the divestiture of AWR, presented within "Gain on sale of business/assets".
(2): During the first quarter of 2021, we recognized a $3.5 million impairment loss related to one of our equity-method investments.


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	(Unaudited)				(Unaudited)
	2021		2020		2021		2020
Capitalization and amortization of internally developed software costs
Cost of sales	$	5,532	$	6,769	$	18,633	$	20,995
Research and development	(525)		302		(1,246)		(2,794)
Provision for income taxes	(1,192)		(1,485)		(3,792)		(3,822)
Total	$	3,815	$	5,586	$	13,595	$	14,379

Liquidity and Capital Resources

Overview

At September 30, 2021, we had $231 million in cash, cash equivalents and short-term investments. Our cash and cash equivalent balances are held in numerous financial institutions throughout the world, including substantial amounts held outside of the U.S., however, all of our short-term investments that are located outside of the U.S. are denominated in the U.S. dollar. The following table presents the geographic distribution of our cash, cash equivalents, and short-term investments as of September 30, 2021:


(in millions)	Domestic	International	Total
Cash and cash equivalents	$95.1	$135.6	$230.7
	41%	59%
Short-term investments	$—	$—	$—
	—%	—%
Total cash, cash equivalents and short-term investments	$95.1	$135.6	$230.7
	41%	59%

The following table presents our working capital, cash and cash equivalents and short-term investments:


	September 30, 2021		December 31,		Increase/
(In thousands)	(unaudited)		2020		(Decrease)

Working capital	$	482,451	$	467,655	$	14,796
Cash and cash equivalents (1)	230,697		260,232		(29,535)
Short-term investments (1)	—		59,923		(59,923)
Total cash, cash equivalents and short-term investments	$	230,697	$	320,155	$	(89,458)

(1) Included in working capital

Our principal sources of liquidity include cash, cash equivalents, cash generated from the sale and maturity of marketable securities, cash flows generated from our operations, cash generated from purchases of common stock through our employee stock purchase plan and available borrowings under our Credit Agreement. The primary drivers of the net increase in working capital between December 31, 2020 and September 30, 2021 were:

◦Cash, cash equivalents, and short-term investments decreased by $89 million for the nine-month period ended September 30, 2021. Additional analysis of the changes in our cash flows for the period ended September 30, 2021 compared to the year ended December 31, 2020 is discussed below;

◦Inventory increased by $43 million. Inventory turns on a trailing twelve month basis were 1.6 at September 30, 2021 and 1.7 at December 31, 2020. The increase in inventory was primarily attributable to an increase in raw materials to support increased demand for our products and minimize supply chain disruptions;

◦Accounts receivable, net increased by $12 million. Days sales outstanding increased to 57 days at September 30, 2021, compared to 56 days at December 31, 2020. The increase in accounts receivable is primarily related to quarterly fluctuations in our net sales;

◦Prepaid and other current assets increased by $21 million, which was primarily related to the timing of annual contract renewals;

◦Accounts payable and accrued expenses increased by $12 million, which was primarily related to amounts owed to suppliers for additional inventory purchases;

◦The current portion of deferred revenue decreased by $11 million, which was primarily related to the timing of annual software maintenance renewals for our enterprise-level licensing arrangements;

◦Accrued compensation increased by $1 million attributable to annual payments under our variable compensation programs related to 2020 performance and severance payments under our 2020 restructuring initiative, offset by accruals related to expected payouts under our 2021 variable compensation programs;

◦Other current liabilities decreased by $17 million which was primarily related to income tax payments and changes in the fair value of foreign currency forward contracts designated as hedging instruments; and

◦Other taxes payable decreased by $4 million primarily related to the timing of payments for VAT and other indirect taxes.

Analysis of Cash Flow

The following table summarizes our cash flow results for the nine months ended September 30, 2021 and 2020.



	Nine Months Ended September 30,
(In thousands)	(unaudited)
	2021		2020
Cash provided by operating activities	$	86,036	$	108,784
Cash used in investing activities	(5,533)		(77,374)
Cash used in financing activities	(107,702)		(29,024)
Effect of exchange rate changes on cash	(2,336)		317
Net change in cash and cash equivalents	(29,535)		2,703
Cash and cash equivalents at beginning of period	260,232		194,616
Cash and cash equivalents at end of period	$	230,697	$	197,319

Operating Activities

Cash provided by operating activities is comprised of net income adjusted for certain items and changes in working capital. Cash flows from operating activities can fluctuate significantly from period to period as working capital needs and the timing of payments for income taxes, variable pay, restructuring activities, and other items impact reported cash flows.

Cash provided by operating activities for the nine months ended September 30, 2021 decreased by $23 million compared to the same period in 2020. This decrease was primarily due to a $120 million decrease in cash provided by changes in operating assets and liabilities during the year, further described below, partially offset by an increase of $97 million in net income adjusted for certain non-cash operating items, including stock-based compensation, depreciation and amortization, and gains on sale of assets/businesses:

•The aggregate of changes in accounts receivable, inventory and accounts payable used net cash of $47 million during the nine months ended September 30, 2021 compared to net cash provided of $19 million in the comparable period in 2020. The amount of cash flow generated from or used by the aggregate of accounts receivable, inventory and accounts payable depends upon the cash conversion cycle, which represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers and can be significantly impacted by the timing of shipments and purchases, as well as collections and payments in a period. We have significantly increased inventory purchases compared to 2020 to support current and anticipated demand for our products and minimize supply chain disruptions.

◦The aggregate of other movements in assets and liabilities used net operating cash of $48 million during the nine months ended September 30, 2021 compared to net operating cash provided of $5 million in the comparable period in 2020. The year over year change is primarily attributable to the timing of payments of federal income taxes, variable compensation programs and severance payments under our 2020 restructuring initiative.

Investing Activities

Cash used by investing activities decreased by $72 million for the nine months ended September 30, 2021 compared to the same period in 2020. This was primarily attributable to a $307 million decrease in cash outflows related to acquisitions and equity-method investments which was partially offset by a $160 million decrease in proceeds received from the sale of our AWR subsidiary in January 2020, a net sale of short-term investments of $60 million in the nine months ended September 30, 2021 compared to a net sale of short-term investments of $145 million during the same period in 2020 and a decrease of $12 million in capital expenditures and internally developed software costs that were eligible for capitalization during the nine months ended September 30, 2021, compared to the same period in 2020.

Financing Activities

Cash used by financing activities increased by $79 million for the nine months ended September 30, 2021 compared to the same period in 2020. This was primarily related to an $88 million decrease in net proceeds received under our term and revolving loan facilities, net of issuance costs, and an increase in cash outflows of $5 million related to our quarterly dividends, partially offset by a decrease in cash outflows of $14 million related to shares repurchased during the comparable period in 2020. (See Note 11 – Authorized shares of common and preferred stock and stock based compensation plans of Notes to Consolidated Financial Statements for additional discussion about our equity compensation plans and share repurchase program).

Contractual Cash Obligations. Information related to our contractual obligations as of December 31, 2020 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations,” in Part II-Item 7 of the Form 10-K. At September 30, 2021, there were no material changes outside the ordinary course of business to our contractual obligations from those reported in our Form 10-K. See Note 8 - Leases of Notes to Consolidated Financial Statements for additional information regarding our non-cancellable operating lease obligations as of September 30, 2021.

Below are the payments due by period for our debt outstanding as of September 30, 2021:


	Payments due by period
(In thousands)	Total		Less than one year	One to three years	Three to five years	More than five years

Revolving line of credit	$	100,000	—	—	100,000	—

Credit Agreement. Refer to Note 13 - Debt and Note 18 - Subsequent Events of Notes to Consolidated Financial Statements for additional details on our secured revolving loan facility. As of September 30, 2021, we had approximately $400 million in available borrowing capacity under the Credit Agreement. Proceeds of additional borrowings made under the Credit Agreement may be used for working capital and other general corporate purposes. We may prepay the loans under the Credit Agreement in whole or in part at any time without premium or penalty. Certain of our future material domestic subsidiaries are required to guaranty our obligations under the Credit Agreement.

Off-Balance Sheet Arrangements. We do not have any off-balance sheet debt. At September 30, 2021, we did not have any relationships with any unconsolidated entities or financial partnerships, such as entities often referred to as structured finance entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we were engaged in such relationships.

Prospective Capital Needs. We believe that our existing cash, cash equivalents and short-term investments, together with cash generated from operations, cash generated from the purchase of common stock through our employee stock purchase plan and available borrowing under our Credit Agreement will be sufficient to cover our working capital needs, capital expenditures, investment requirements, commitments, payment of dividends to our stockholders and repurchases of our common stock for at least the next 12 months. We may also seek to pursue additional financing or to raise additional funds by seeking an additional increase in our secured revolving line of credit under our Credit Agreement or selling equity or debt to the public or in private transactions from time to time. If we elect to raise additional funds, we may not be able to obtain such funds on a timely basis or on acceptable terms, if at all. If we raise additional funds by issuing additional equity or convertible debt securities, the ownership percentages of our existing stockholders would be reduced. In addition, the equity or debt securities that we issue may have rights, preferences or privileges senior to those of our common stock.

Although we believe that we have sufficient capital to fund our operating activities for at least the next 12 months, our future capital requirements may vary materially from those now planned. We anticipate that the amount of capital we will need in the future will depend on many factors, including:

•payment of dividends to our stockholders;

•required levels of research and development and other operating costs;

•our business, product, capital expenditure and research and development plans, and product and technology roadmaps;

•acquisitions of other businesses, assets, products or technologies;

•repurchase of our common stock;

•the overall levels of sales of our products and gross profit margins;

•the levels of inventory and accounts receivable that we maintain;

•general economic and political uncertainty and specific conditions in the markets we address, including any volatility in the industrial economy in the various geographic regions in which we do business;

•the inability of certain of our customers who depend on credit to have access to their traditional sources of credit to finance the purchase of products from us, which may lead them to reduce their level of purchases or to seek credit or other accommodations from us;

•capital improvements for facilities;

•our relationships with suppliers and customers; and

•the amount of proceeds received as a result of our employee stock purchase plan.

Recently Issued Accounting Pronouncements

See Note 1 – Basis of presentation in Notes to Consolidated Financial Statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Changes in currency exchange rates and interest rates are our primary financial market risks. Quantitative and qualitative disclosures about market risk appear in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in Part II of our Form 10-K and the material changes during the nine months ended September 30, 2021 to this information reported in our Form 10-K are described below.

Interest Expense Risk

Our borrowings under our Credit Agreement bear interest at a variable rate which exposes us to market risk related to changes in interest rates. We have not entered into derivative transactions related to our borrowing arrangements. The primary base interest rate is LIBOR. Assuming the outstanding balance on our floating rate indebtedness remains constant over a year, a 100-basis point increase in the interest rate would decrease annual net income and cash flow by less than $1 million. We do not expect changes in interest rates to have a material adverse effect on our income or our cash flows in 2021. However, there is no assurance that interest rates will not significantly change in the future.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of our management, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of September 30, 2021, to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the third quarter of 2021, which were identified in connection with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material litigation. However, in the ordinary course of our business, we have in the past, are currently and will likely become involved in various legal proceedings, claims, and regulatory, tax or government inquiries and investigations, and could incur uninsured liability in any one or more of them. We also periodically receive notifications from various third parties related to alleged infringement of patents or intellectual property rights, commercial disputes or other matters. No assurances can be given with respect to the extent or outcome of any investigation, litigation or dispute.

Item 1A. Risk Factors

Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in Part I, Item 1A of our Form 10-K under the heading “Risk Factors,” any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price.

The following risk factors are provided to update the risk factors previously disclosed under the heading “Risk Factors” in our Form 10-K. The developments described in the additional risk factors presented below have heightened, or in some cases manifested, certain of the risks disclosed in the other risk factors identified in the “Risk Factors” section of our Form 10-K.

A Global Shortage of Key Components Has and May Continue to Adversely Affect Our Business and Result of Operations. Various factors, including increased demand for certain components and production delays due to COVID-19 and other natural events and disasters, are contributing to shortages of certain components used in our products and increased difficulties in our ability to obtain a consistent supply of materials at stable pricing levels. The supply shortages have increased the costs and lead times of certain components. Longer lead times may cause a significant disruption to our production activities, which could have a substantial adverse effect on our financial condition or results of operations. If we are unsuccessful in resolving any such component shortages in a timely manner, we will experience a significant impact on the timing of revenue, a possible loss of revenue, or an increase in manufacturing costs, any of which would have a material adverse impact on our operating results.

We Continue to Face Significant Risks Related to Adverse Public Health Matters, Including Epidemics and Pandemics such as the COVID-19 Pandemic. Any outbreaks of contagious diseases and other adverse public health developments in countries where we operate could have a material and adverse effect on our business, financial condition, liquidity and results of operations. For example, the COVID-19 pandemic has adversely affected our operations throughout the world, as well as the facilities of our suppliers and customers. The COVID-19 pandemic caused widespread disruptions to our operations throughout 2020, particularly during the first half of the year. Although we have not experienced a significant reduction in our overall productivity due to the COVID-19 pandemic, we have experienced some disruptions to our operations, and expect to continue to experience such disruptions to our operations. These disruptions have included and may continue to include, depending on the specific location, logistical challenges and limitations, reduced demand from certain customers, and government regulations that require us to adjust or restrict our operations at certain of our facilities, incur additional costs, adapt to challenges presented by travel restrictions and “work-from-home” orders and/or require employee vaccinations. The extent to which the COVID-19 pandemic will continue to impact our business and financial results going forward will be dependent on future developments such as the length and severity of the COVID-19 pandemic, future government regulations and actions in response to the COVID-19 pandemic, the timing, availability and effectiveness of vaccines, as well as the willingness of our employees to receive such vaccine, and the overall impact of the COVID-19 pandemic on the global economy and capital markets, among many other factors, all of which remain uncertain and unpredictable. In October 2021, to remain compliant with the deadline established in the recent U.S. federal executive order applicable to U.S. federal contractors, we notified our employees that we will require all US employees to be fully vaccinated against the COVID-19 virus by December 8 (other than employees with certain legally qualifying exemptions).

In addition, the COVID-19 pandemic could directly impact the health of our management team and other employees. It is impossible to predict the overall future impact of the COVID-19 pandemic on our business, financial condition, liquidity and financial results, and there can be no assurance that the COVID-19 pandemic will not have a material and adverse effect on our financial results in the future during any quarter or period in which we are affected.

The COVID-19 pandemic also increases the likelihood and potential severity of other risks to the Company (including some discussed separately within this Item 1A. Risk Factors), including but not limited to, the following:

•We may be required to implement certain public health protocols in order to continue doing business with certain customers or operate in certain jurisdictions, including additional mandatory vaccination or ongoing testing programs for a subset of our employee population. Complying with these requirements could result in additional costs and challenges with employee retention. Failure to comply with these requirements could have a significant impact on our sales to certain customers.

•A significant subset of our employee population is currently in a remote work environment in an effort to mitigate the spread of COVID-19. This change may exacerbate certain risks to our business, including an increased risk of phishing and other cybersecurity attacks, an increased risk of challenges related to hiring, training, and retaining personnel, and an increased risk of delays or disruptions to our product development, sales, marketing, manufacturing and support operations that we cannot fully mitigate through remote or other alternative work arrangements.

•Protracted economic uncertainty could negatively affect the financial condition of our customers or suppliers, which may result in an increase in bankruptcies or insolvencies, a delay in payments and decreased sales.

•A scarcity of resources or other hardships caused by the COVID-19 pandemic may result in increased geopolitical tensions which may cause governments and/or other entities to take actions that may have a significant negative impact on our ability or the ability of our suppliers and customers to conduct business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information as of September 30, 2021 with respect to the shares of our common stock that we repurchased during the third quarter of 2021.


Period	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs	Maximum number of shares that may yet be purchased under the plans or programs (1)

July 1, 2021 to July 31, 2021	—	$	—	—	1,609,943

August 1, 2021 to August 31, 2021	—	$	—	—	1,609,943

September 1, 2021 to September 30, 2021	599,066	$	41.73	599,066	1,010,877
Total	599,066	$	41.73	599,066	1,010,877
(1) On April 21, 2010, our Board of Directors authorized a program to repurchase shares of our common stock from time to time, depending on market conditions and other factors. The Board of Directors amended such program several times over the years to increase the number of shares that may be purchased under the program. Most recently, on October 23, 2019, our Board of Directors amended the program to increase the number of shares that may be repurchased by 3,000,000 shares. At September 30, 2021, there were 1,010,877 shares remaining available for repurchase under the stock repurchase program. This program does not have an expiration date nor does it obligate the Company to acquire any specific number of shares. Under the program, shares may be repurchased in privately negotiated and/or open market transactions.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.


EXHIBITS

3.1(1)			Certificate of Incorporation, as amended, of the Registrant, effective May 14, 2013
3.2(2)			Amended and Restated By-laws of the Registrant effective August 1, 2021















































10.1*			Executive Employment Agreement , between the Registrant and Scott Rust , effective October 1, 2021†
10.2*			National Instruments Corporation Executive Incentive Program, as amended and restated, effective October 11, 2021†
31.1*			Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*			Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**			Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101*			Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q






104*			Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
(1)			Incorporated by reference to Exhibit 3.1 to the Registrant's Form 10-K for the fiscal year ended December 31, 2013, filed with the Commission on February 20, 2014
(2)			Incorporated by reference to Exhibit 3.2 to the Registrant's Form 10-Q for the quarterly period ended June 30, 2021, filed with the Commission on August 2, 2021













































*Filed herewith
**Furnished herewith
† Management Contract or Compensatory Plan or Arrangement

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 1, 2021


NATIONAL INSTRUMENTS CORPORATION
By: /s/ Karen Rapp
Karen Rapp
EVP, Chief Financial Officer
(Principal Financial Officer)


Title	Applicable Date	Identifying Registration Number or Brief Description


By: /s/ Eric Starkloff
Eric Starkloff
Chief Executive Officer
Date: November 1, 2021


By: /s/ Karen Rapp
Karen Rapp
Chief Financial Officer
Date: November 1, 2021